
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-a68b4900.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-0a3f24ce.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Repurposing Asparaginase Therapy to Target Cisplatin‐Resistant Cancer Cells - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="4DDE475F89B71A531B475F004892F12F.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="blackwellopen">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12335911/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Fundamental &amp; Clinical Pharmacology">
<meta name="citation_title" content="Repurposing Asparaginase Therapy to Target Cisplatin‐Resistant Cancer Cells">
<meta name="citation_author" content="Jiantao Wang">
<meta name="citation_author_institution" content="Science for Life Laboratory (SciLifeLab), Department of Oncology‐Pathology, Karolinska Institutet, Stockholm, Sweden">
<meta name="citation_author_institution" content="Department of Radiation Oncology, West China Hospital, Sichuan University, Chengdu, China">
<meta name="citation_author_institution" content="Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, China">
<meta name="citation_author" content="Nasim Pouryaghoub">
<meta name="citation_author_institution" content="Science for Life Laboratory (SciLifeLab), Department of Oncology‐Pathology, Karolinska Institutet, Stockholm, Sweden">
<meta name="citation_author" content="Robert Strauss">
<meta name="citation_author_institution" content="Danish Cancer Institute, Genome Integrity Group, Copenhagen, Denmark">
<meta name="citation_author" content="Jiri Bartek">
<meta name="citation_author_institution" content="Danish Cancer Institute, Genome Integrity Group, Copenhagen, Denmark">
<meta name="citation_author_institution" content="Science for Life Laboratory (SciLifeLab), Division of Genome Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden">
<meta name="citation_author" content="Si Min Zhang">
<meta name="citation_author_institution" content="Science for Life Laboratory (SciLifeLab), Department of Oncology‐Pathology, Karolinska Institutet, Stockholm, Sweden">
<meta name="citation_author" content="Sean G Rudd">
<meta name="citation_author_institution" content="Science for Life Laboratory (SciLifeLab), Department of Oncology‐Pathology, Karolinska Institutet, Stockholm, Sweden">
<meta name="citation_publication_date" content="2025 Aug 10">
<meta name="citation_volume" content="39">
<meta name="citation_issue" content="5">
<meta name="citation_firstpage" content="e70044">
<meta name="citation_doi" content="10.1111/fcp.70044">
<meta name="citation_pmid" content="40784667">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12335911/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12335911/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12335911/pdf/FCP-39-0.pdf">
<meta name="description" content="Cisplatin and its derivatives remain a cornerstone in the treatment of solid malignancies. Resistance is a major factor limiting their clinical utility. In the present study, we set out to interrogate therapeutic approaches to target ...">
<meta name="og:title" content="Repurposing Asparaginase Therapy to Target Cisplatin‐Resistant Cancer Cells">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Cisplatin and its derivatives remain a cornerstone in the treatment of solid malignancies. Resistance is a major factor limiting their clinical utility. In the present study, we set out to interrogate therapeutic approaches to target ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12335911/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-testid="header" data-header >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            
                <a class="ncbi-header__logo-container" href="https://www.ncbi.nlm.nih.gov/">
                    <img alt="
                                  NCBI home page
                              "
                         class="ncbi-header__logo-image"
                         src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg" />
                </a>
            

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            


    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true"    >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                


    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true"    >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                


    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true"    data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                


    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true"    data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
    

    Dashboard

    
</a>

                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
    

    Publications

    
</a>

                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
    

    Account settings

    
</a>

                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-testid="searchPanel"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      aria-describedby="search-field-desktop-navigation-help-text"
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only"
                           data-testid="label"
                           for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           data-testid="textInput"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    data-testid="button"
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  role="search">
                <label class="usa-sr-only" for="search-field">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="search" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
    

    Dashboard

    
</a>

                        </li>
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
    

    Publications

    
</a>

                        </li>
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
    

    Account settings

    
</a>

                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        <a class="usa-link" href="https://www.ncbi.nlm.nih.gov/pmc/advanced/" data-ga-action="featured_link" data-ga-label="advanced_search">
                            Advanced Search
                        </a>
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12335911">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1111/fcp.70044"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/FCP-39-0.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12335911%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12335911/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12335911/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12335911/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-blackwellopen.png" alt="Wiley Open Access Collection logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Wiley Open Access Collection" title="Link to Wiley Open Access Collection" shape="default" href="https://doi.org/10.1111/fcp.70044" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Fundam Clin Pharmacol</button></div>. 2025 Aug 10;39(5):e70044. doi: <a href="https://doi.org/10.1111/fcp.70044" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1111/fcp.70044</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22Fundam%20Clin%20Pharmacol%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Fundam%20Clin%20Pharmacol%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Fundam%20Clin%20Pharmacol%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Fundam%20Clin%20Pharmacol%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Repurposing Asparaginase Therapy to Target Cisplatin‐Resistant Cancer Cells</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wang%20J%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Jiantao Wang</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Jiantao Wang</span></h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Science for Life Laboratory (SciLifeLab), Department of Oncology‐Pathology, Karolinska Institutet, Stockholm, Sweden</div>
<div class="p">
<sup>
<sup>2</sup>
</sup>Department of Radiation Oncology, West China Hospital, Sichuan University, Chengdu, China</div>
<div class="p">
<sup>
<sup>3</sup>
</sup>Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, China</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wang%20J%22%5BAuthor%5D" class="usa-link"><span class="name western">Jiantao Wang</span></a>
</div>
</div>
<sup>1,</sup><sup>2,</sup><sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Pouryaghoub%20N%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Nasim Pouryaghoub</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Nasim Pouryaghoub</span></h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Science for Life Laboratory (SciLifeLab), Department of Oncology‐Pathology, Karolinska Institutet, Stockholm, Sweden</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Pouryaghoub%20N%22%5BAuthor%5D" class="usa-link"><span class="name western">Nasim Pouryaghoub</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Strauss%20R%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Robert Strauss</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Robert Strauss</span></h3>
<div class="p">
<sup>
<sup>4</sup>
</sup>Danish Cancer Institute, Genome Integrity Group, Copenhagen, Denmark</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Strauss%20R%22%5BAuthor%5D" class="usa-link"><span class="name western">Robert Strauss</span></a>
</div>
</div>
<sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Bartek%20J%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Jiri Bartek</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Jiri Bartek</span></h3>
<div class="p">
<sup>
<sup>4</sup>
</sup>Danish Cancer Institute, Genome Integrity Group, Copenhagen, Denmark</div>
<div class="p">
<sup>
<sup>5</sup>
</sup>Science for Life Laboratory (SciLifeLab), Division of Genome Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Bartek%20J%22%5BAuthor%5D" class="usa-link"><span class="name western">Jiri Bartek</span></a>
</div>
</div>
<sup>4,</sup><sup>5</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhang%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Si Min Zhang</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Si Min Zhang</span></h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Science for Life Laboratory (SciLifeLab), Department of Oncology‐Pathology, Karolinska Institutet, Stockholm, Sweden</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhang%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Si Min Zhang</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Rudd%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Sean G Rudd</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Sean G Rudd</span></h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Science for Life Laboratory (SciLifeLab), Department of Oncology‐Pathology, Karolinska Institutet, Stockholm, Sweden</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Rudd%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Sean G Rudd</span></a>
</div>
</div>
<sup>1,</sup><sup>✉</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="fcp70044-aff-0001">
<sup>
<sup>1</sup>
</sup>Science for Life Laboratory (SciLifeLab), Department of Oncology‐Pathology, Karolinska Institutet, Stockholm, Sweden</div>
<div id="fcp70044-aff-0002">
<sup>
<sup>2</sup>
</sup>Department of Radiation Oncology, West China Hospital, Sichuan University, Chengdu, China</div>
<div id="fcp70044-aff-0003">
<sup>
<sup>3</sup>
</sup>Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, China</div>
<div id="fcp70044-aff-0004">
<sup>
<sup>4</sup>
</sup>Danish Cancer Institute, Genome Integrity Group, Copenhagen, Denmark</div>
<div id="fcp70044-aff-0005">
<sup>
<sup>5</sup>
</sup>Science for Life Laboratory (SciLifeLab), Division of Genome Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden</div>
<div class="author-notes p">
<div class="fn" id="correspondenceTo">
<sup>*</sup><p class="display-inline">

<strong>Correspondence:</strong>
 
Sean G. Rudd (<span>sean.rudd@scilifelab.se</span>)
</p>
</div>
<div class="fn" id="_fncrsp93pmc__">
<sup>✉</sup><p class="display-inline">Corresponding author.</p>
</div>
</div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Revised 2025 Jul 25; Received 2025 Jun 18; Accepted 2025 Jul 28; Issue date 2025 Oct.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© 2025 The Author(s). <em>Fundamental &amp; Clinical Pharmacology</em> published by John Wiley &amp; Sons Ltd on behalf of Société Française de Pharmacologie et de Thérapeutique.</div>
<p>This is an open access article under the terms of the <a href="https://creativecommons.org/licenses/by/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/licenses/by/4.0/</a> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12335911  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40784667/" class="usa-link">40784667</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>ABSTRACT</h2>
<section id="fcp70044-sec-0001"><h3 class="pmc_sec_title">Background</h3>
<p>Cisplatin and its derivatives remain a cornerstone in the treatment of solid malignancies. Resistance is a major factor limiting their clinical utility.</p></section><section id="fcp70044-sec-0002"><h3 class="pmc_sec_title">Objectives</h3>
<p>In the present study, we set out to interrogate therapeutic approaches to target cisplatin‐resistant cancer cells. We focused on therapies exploiting metabolic pathways that are altered in drug‐resistant cells. We sought to find an existing therapy that has monotherapy efficacy against cisplatin‐resistant cancer cells that can also re‐sensitize to cisplatin.</p></section><section id="fcp70044-sec-0003"><h3 class="pmc_sec_title">Methods</h3>
<p>We used lung and ovarian cancer cell lines with acquired resistance to cisplatin together with drug sensitivity assays, conducted both with monotherapies and cisplatin combinations.</p></section><section id="fcp70044-sec-0004"><h3 class="pmc_sec_title">Results</h3>
<p>We show that cancer cell lines with acquired resistance to cisplatin have altered levels of enzymes involved in glutamine metabolism, which can result in differential sensitivity to targeted agents. We show that expression of one of these enzymes—the glutamate‐cystine antiporter SLC7A11, up‐regulated 6‐fold in a cisplatin‐resistant lung cancer cell line—has potential prognostic significance in lung cancer but not ovarian cancer. After identifying a common dependency of cisplatin‐resistant cancer cells upon extracellular glutamine, we then evaluate the utility of the long‐standing anti‐leukemic therapy asparaginase (ASNase)—which possesses both asparaginase and glutaminase activity—as a potential approach. We show ASNase preferentially inhibits the proliferation of cisplatin‐resistant cancer cells and can potentially re‐sensitize these cells to cisplatin.</p></section><section id="fcp70044-sec-0005"><h3 class="pmc_sec_title">Conclusions</h3>
<p>Our results underpin the prevalence of altered metabolism in cisplatin‐resistant cells and highlight the potential utility of re‐purposing ASNase to target these cells, warranting further investigation.</p></section><section id="kwd-group1" class="kwd-group"><p><strong>Keywords:</strong> asparaginase (ASNase), chemoresistance, cisplatin, glutamine, metabolic rewiring, SLC7A11</p></section></section><hr class="headless">
<h3>Abbreviations</h3>
<dl class="def-list" id="fcp70044-dl-0001">
<dt id="fcp70044-li-0001">ASNase</dt>
<dd id="fcp70044-li-0002"><p>asparaginase</p></dd>
<dt id="fcp70044-li-0003">CDDP</dt>
<dd id="fcp70044-li-0004"><p>cisplatin</p></dd>
<dt id="fcp70044-li-0005">GLS</dt>
<dd id="fcp70044-li-0006"><p>glutaminase</p></dd>
<dt id="fcp70044-li-0007">GS</dt>
<dd id="fcp70044-li-0008"><p>glutamine synthetase</p></dd>
<dt id="fcp70044-li-0009">GSH</dt>
<dd id="fcp70044-li-0010"><p>glutathione</p></dd>
<dt id="fcp70044-li-0011">HSA</dt>
<dd id="fcp70044-li-0012"><p>highest single agent</p></dd>
<dt id="fcp70044-li-0013">SLC7A11</dt>
<dd id="fcp70044-li-0014"><p>solute carrier family 7 member 11</p></dd>
<dt id="fcp70044-li-0015">ZIP</dt>
<dd id="fcp70044-li-0016"><p>zero interaction potency</p></dd>
</dl>
<section id="fcp70044-sec-0006"><h2 class="pmc_sec_title">1. Introduction</h2>
<p>Conventional chemotherapeutic agents remain a fundamental treatment modality for patients with cancer [<a href="#fcp70044-bib-0001" class="usa-link" aria-describedby="fcp70044-bib-0001">1</a>]. The platinum derivative cisplatin (cis‐diamminedichloroplatinum; CDDP) is a cornerstone compound effective in the treatment of a variety of solid malignancies, including cancers of the lung, bladder, and ovaries, amongst others. While a good initial response is common, the duration of this response varies greatly and eventual disease relapse can occur, which is a major clinical problem [<a href="#fcp70044-bib-0002" class="usa-link" aria-describedby="fcp70044-bib-0002">2</a>]. Thus, identification of actionable therapeutic strategies to target cisplatin‐resistant cancer cells is vital.</p>
<p>The molecular mode‐of‐action of cisplatin and platinum‐derived compounds is principally understood to center around crosslinking of DNA strands, which are cytotoxic DNA lesions that prevent essential metabolic processes such as DNA replication and transcription [<a href="#fcp70044-bib-0003" class="usa-link" aria-describedby="fcp70044-bib-0003">3</a>, <a href="#fcp70044-bib-0004" class="usa-link" aria-describedby="fcp70044-bib-0004">4</a>]. To do this, cisplatin, a prodrug, is first activated inside cancer cells by aquation, which occurs spontaneously in the cytoplasm owing to lower intracellular chloride concentrations compared to the extracellular milieu. This produces a potent electrophile that can react with biological molecules in both the cytosol and nucleus, including the bases in the DNA duplex [<a href="#fcp70044-bib-0003" class="usa-link" aria-describedby="fcp70044-bib-0003">3</a>, <a href="#fcp70044-bib-0004" class="usa-link" aria-describedby="fcp70044-bib-0004">4</a>]. Following cytotoxic DNA damage, DNA damage signaling will promote induction of the mitochondrial apoptotic pathway resulting in cell death, which can also be supported by cytosolic targets of aquated‐cisplatin [<a href="#fcp70044-bib-0005" class="usa-link" aria-describedby="fcp70044-bib-0005">5</a>]. Cisplatin can be limited by its severe side effects, primarily due to its lack of specificity for tumor cells. In its derivative, carboplatin, the chloride ligands are replaced with a more stable dicarboxylate group, resulting in a slower activation rate and reduced toxicity. However, the DNA‐binding component remains unchanged [<a href="#fcp70044-bib-0003" class="usa-link" aria-describedby="fcp70044-bib-0003">3</a>]. Oxaliplatin, another derivative, introduces further structural modifications that lead to the formation of bulkier DNA adducts, which can evade some resistance mechanisms and enhance anti‐cancer activity [<a href="#fcp70044-bib-0003" class="usa-link" aria-describedby="fcp70044-bib-0003">3</a>].</p>
<p>Given this multi‐step mode of action of cisplatin and platinum‐derived agents, multiple resistance mechanisms exist, which have been widely documented in both the clinical and preclinical settings [<a href="#fcp70044-bib-0002" class="usa-link" aria-describedby="fcp70044-bib-0002">2</a>, <a href="#fcp70044-bib-0003" class="usa-link" aria-describedby="fcp70044-bib-0003">3</a>, <a href="#fcp70044-bib-0005" class="usa-link" aria-describedby="fcp70044-bib-0005">5</a>, <a href="#fcp70044-bib-0006" class="usa-link" aria-describedby="fcp70044-bib-0006">6</a>, <a href="#fcp70044-bib-0007" class="usa-link" aria-describedby="fcp70044-bib-0007">7</a>]. These include reduced drug uptake or increased drug efflux, elevated DNA repair proficiency to remove cytotoxic cisplatin adducts, or, alternatively, increased tolerance of cisplatin adducts and failure to induce apoptotic cell death. In addition, aquated cisplatin can be detoxified from cells by reacting with thiol‐containing molecules, such as glutathione (GSH).</p>
<p>GSH is a tripeptide consisting of 𝛾‐glutamate, cysteine, and glycine, with a major role in maintaining redox homeostasis in cells by reacting with harmful by‐products of aerobic metabolism [<a href="#fcp70044-bib-0008" class="usa-link" aria-describedby="fcp70044-bib-0008">8</a>]. Owing to the nucleophile thiol residue which lacks steric hindrance and is highly abundant inside cells, the thiol in GSH can react with electrophiles such as aquated‐cisplatin, thereby protecting cells against this cytotoxic compound. The cysteine component of GSH is generated from cystine, which is imported by antiporter SLC7A11 at the expense of exporting glutamate. The glutamate component of GSH is derived from glutamine, a non‐essential amino acid that is highly abundant in the human body [<a href="#fcp70044-bib-0009" class="usa-link" aria-describedby="fcp70044-bib-0009">9</a>]. Glutamine can be obtained through diet and can also be synthesized inside cells by glutamine synthetase (GS). Extracellular glutamine is imported into cells by soluble carrier transporters such as ASCT2 (SLC1A5). Within cells, glutamine is involved in many metabolic processes, including nucleotide biosynthesis, energy production via the TCA cycle, and generation of the antioxidant GSH to maintain redox homeostasis [<a href="#fcp70044-bib-0009" class="usa-link" aria-describedby="fcp70044-bib-0009">9</a>].</p>
<p>In the present study, we sought to evaluate therapeutic approaches to target cisplatin‐resistant cancer cells. Using cell models with acquired resistance to this agent, we observed that cisplatin resistance was accompanied by changes in glutamine metabolic enzymes that can lead to differential sensitivity to targeted agents. We identify a dependency of cisplatin‐resistant cells upon extracellular glutamine and subsequently evaluate the ability of the approved anti‐leukemic therapy asparaginase (ASNase) to target these cells.</p></section><section id="fcp70044-sec-0007"><h2 class="pmc_sec_title">2. Materials and Methods</h2>
<section id="fcp70044-sec-0008"><h3 class="pmc_sec_title">2.1. Cell Lines</h3>
<p>Human lung adenocarcinoma cell line HCC4006 was authenticated (Microsynth) and thereafter cultured in escalating doses of clinical‐grade cisplatin (#146262, Hospira Nordic AB) to generate a cell model with acquired resistance. The starting dose of 1 μM cisplatin was raised to 2.5 μM and thereafter 5 μM over a time course of 3 months. HCC4006 cisplatin‐resistant cells were subsequently cultured in 5 μM cisplatin for 3 further months. Human ovarian cancer A2780 and cisplatin‐resistant derivative A2780cis were from the European Collection of Authenticated Cell Cultures (ECACC, Sigma‐Aldrich). All cell lines were cultured in RPMI 1640 GlutaMAX supplemented with 10% heat‐inactivated fetal bovine serum (FBS) and penicillin–streptomycin (100 U/mL and 100 μg/mL, respectively). Culture medium was purchased from ThermoFisher Scientific. Glutamine withdrawal experiments were conducted with glutamine‐free RPMI 1640 medium (#21870076, ThermoFisher Scientific). Cells were grown at 37 °C in 5% CO<sub>2</sub> humidified incubators, and cultures were regularly monitored and tested negative for the presence of mycoplasma using a commercial biochemical test (MycoAlert, Lonza).</p></section><section id="fcp70044-sec-0009"><h3 class="pmc_sec_title">2.2. Drugs</h3>
<p>Cisplatin (CDDP; Sigma‐Aldrich, #P4394) was prepared in 2 mM stock in water or PBS and stored at 4 °C. Asparaginase (ASNase, Sigma‐Aldrich, #A3809) was prepared in water to a stock concentration of 500 U/mL and stored at −20 °C. Erastin (Sigma‐Aldrich, #E7781), RSL‐3 (Sigma‐Aldrich, #SML2234), and Telaglenastat (CB‐839, MedChemExpress, #HY‐12248) were prepared in DMSO at a concentration of 10 mM and stored at −20 °C.</p></section><section id="fcp70044-sec-0010"><h3 class="pmc_sec_title">2.3. Transfections</h3>
<p>Transfections were performed using INTERFERin (Polyplus Transfection). SLC7A11‐targeting siRNA (Hs_SLC7A11_2 FlexiTube siRNA, #SI00104902, Qiagen) and control siRNA (All Stars Negative Control, Qiagen) were transfected at a 10 nM final concentration.</p></section><section id="fcp70044-sec-0011"><h3 class="pmc_sec_title">2.4. Immunoblots</h3>
<p>Cells were scraped in lysis buffer (50 mM Tris–HCl pH 8, 150 mM NaCl, 1 mM EDTA, 1% Triton X‐100, 0.1% SDS) supplemented with cOmplete EDTA‐free protease inhibitor cocktail (Roche) and Halt phosphatase inhibitor cocktail (Thermo Fisher). Samples were incubated on ice for 30 min to 1 h with occasional vortexing before centrifugation to pellet insoluble material. The Pierce BCA Protein Assay Kit (Thermo Fisher) was used to determine the concentration of the remaining soluble fraction, and samples with equal total protein quantity were prepared with Laemmli Sample Buffer (Bio‐Rad) before denaturation at 95 °C for 5 min. SDS–PAGE was performed using a Bio‐Rad setup with Criterion TGX 4–20% gels (Bio‐Rad) and proteins were transferred to a nitrocellulose membrane using Trans‐Blot Turbo Transfer System (Bio‐Rad), all according to the manufacturer's instructions. Membranes were blocked in Odyssey Blocking Buffer (Li‐Cor) and probed with primary and then species‐appropriate IRDye‐conjugated secondary antibodies (Li‐Cor) before visualization on an Odyssey Fc Imaging System (Li‐Cor). Densitometry analyses were performed using ImageStudio Software (version 6.0, Li‐Cor), and values were normalized to a loading control. Primary antibodies used in this study: xCT/SLC7A11 (Cell Signaling, #12691S, 1:1000), GLS1 (abcam, #ab156876, 1:2000), GLS2 (abcam, #ab113509, 1:1000), GS (abcam, #ab176562, 1:1000), ASCT2 (Sigma‐Aldrich, #ABN73, 1:1000), and α‐tubulin (abcam, #ab7291: 1:5000).</p></section><section id="fcp70044-sec-0012"><h3 class="pmc_sec_title">2.5. Proliferation Inhibition Assays</h3>
<p>Inhibition of cell proliferation by monotherapy or combination treatment was determined by resazurin reduction assay as previously described [<a href="#fcp70044-bib-0010" class="usa-link" aria-describedby="fcp70044-bib-0010">10</a>]. Compounds prepared either in DMSO (erastin, RSL‐3, CB‐839; 10 mM) or 0.3% Tween‐20 (CDDP, 2 mM; ASNase, 250 U/mL) were dispensed in dilution series into clear bottomed 384‐well plates (#3764, Corning) using the D300e digital dispenser (Tecan). Solvents were normalized across each plate. Cell suspensions were prepared and dispensed using a MultiDrop (Thermo Fisher). Plates were incubated at 37 °C and 5% CO<sub>2</sub> for 72 h in a humidity chamber until resazurin (#<a href="https://www.ncbi.nlm.nih.gov/nuccore/R17017" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">R17017</a>, Sigma‐Aldrich) dissolved in PBS was added to a final concentration of 0.01 mg/mL. Fluorescence at 530/590 nm (ex/em) was measured after 4–6 h resazurin incubation with Hidex Sense Microplate Reader. Fluorescence intensity for each well was normalized to the average of control wells on the same plate containing cells with solvent (100% viability control) and medium with solvent (0% viability control). The data were analyzed using a four‐parameter logistic model in Prism 10 (GraphPad Software). For calculation of area under the dose–response data, the drug concentration values were log<sub>10</sub> transformed, and the AUC was calculated in Prism 10 (GraphPad Software). For determination of drug combination effects, relative cell viability measurements across a drug matrix were analyzed using SynergyFinder+ [<a href="#fcp70044-bib-0011" class="usa-link" aria-describedby="fcp70044-bib-0011">11</a>, <a href="#fcp70044-bib-0012" class="usa-link" aria-describedby="fcp70044-bib-0012">12</a>] with the zero interaction potency (ZIP), highest single agent (HSA) and Bliss metrics. Synergy summary scores were derived from the average of the synergy scores across the entire dose–response landscape.</p></section><section id="fcp70044-sec-0013"><h3 class="pmc_sec_title">2.6. Colony Outgrowth Assay</h3>
<p>Cells (100–200 per well) were seeded into six‐well plates. To assess glutamine dependence, cells were seeded in glutamine‐free media (#21870076, ThermoFisher Scientific). To assess ASNase sensitivity, cells were seeded in media supplemented with ASNase. Cells were then incubated for 12–14 days, during which media with or without ASNase supplementation was replaced every 3–4 days. Following incubation, media were removed, and the wells were washed carefully in PBS before the colonies were stained with 4% methylene blue (#M9140, Sigma‐Aldrich, Sweden) in methanol for 20 min.</p></section><section id="fcp70044-sec-0014"><h3 class="pmc_sec_title">2.7. Survival Analyses</h3>
<p>Overall survival (OS) analyses for <em>SLC7A11</em> expression in lung adenocarcinoma (LUAD) and ovarian serous cystadenocarcinoma (OV) were performed using the Gene Expression Profiling Interactive Analysis tool (GEPIA; <a href="http://gepia.cancer-pku.cn" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://gepia.cancer‐pku.cn</a>), a web‐based platform integrating RNA‐seq expression data from TCGA and GTEx [<a href="#fcp70044-bib-0013" class="usa-link" aria-describedby="fcp70044-bib-0013">13</a>]. The “Survival Analysis” module was used with default settings, applying median expression as the cutoff to stratify high vs. low expression cohorts. Kaplan–Meier (KM) plots and hazard ratios (HR) with 95% confidence intervals (CI) were generated automatically by GEPIA. Log‐rank <em>p</em> values were used to assess statistical significance.</p>
<p>In addition, the KM‐Plotter tool (<a href="https://kmplot.com/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://kmplot.com/</a>) for lung [<a href="#fcp70044-bib-0014" class="usa-link" aria-describedby="fcp70044-bib-0014">14</a>] and ovarian [<a href="#fcp70044-bib-0015" class="usa-link" aria-describedby="fcp70044-bib-0015">15</a>] cancer was used. The default settings were selected, analyzing all cohorts and applying a median expression cutoff to stratify high vs. low expression. KM plots and HR values were generated automatically, and log‐rank <em>p</em> values were used to assess statistical significance.</p></section><section id="fcp70044-sec-0015"><h3 class="pmc_sec_title">2.8. Statistical Analyses</h3>
<p>Statistical analyses were conducted using GraphPad Prism 10 software. Specific statistical test details are indicated in the corresponding figure legends. Statistical significance is defined as <em>p</em> &lt; 0.05, unless otherwise stated. Asterisks in figures signify statistical significance (*<em>p</em> ≤ 0.05, **<em>p</em> ≤ 0.01, ***<em>p</em> ≤ 0.001, ****<em>p</em> ≤ 0.0001).</p></section></section><section id="fcp70044-sec-0016"><h2 class="pmc_sec_title">3. Results</h2>
<section id="fcp70044-sec-0017"><h3 class="pmc_sec_title">3.1. Acquired Resistance to Cisplatin Can Lead to Changes in Glutamine Metabolic Enzymes</h3>
<p>To conduct our study, we used cancer cell lines with acquired resistance to cisplatin derived from the lung adenocarcinoma cell line HCC4006 and the ovarian cancer cell line A2780. The parental cell lines and their cisplatin‐resistant derivatives were subjected to a 3‐day incubation of a cisplatin dose–response in a proliferation inhibition assay, which confirmed acquired resistance to this therapy (Figure <a href="#fcp70044-fig-0001" class="usa-link">1a</a>). Next, we performed immunoblot analysis of lysates from the cell line pairs to determine the protein levels of enzymes involved in glutamine metabolism (Figure <a href="#fcp70044-fig-0001" class="usa-link">1b,c</a>). Glutamine importer ASCT2 and glutaminases GLS1/2 were expressed in the parental and cisplatin‐resistant cell line pairs; however, glutamine synthetase (GS) and the glutamate‐cystine antiporter SLC7A11 showed strong differential expression (Figure <a href="#fcp70044-fig-0001" class="usa-link">1c</a>). Specifically, cisplatin‐resistant A2780 cell lines had no detectable GS protein, while cisplatin‐resistant HCC4006 had elevated protein levels of SLC7A11 (Figure <a href="#fcp70044-fig-0001" class="usa-link">1c</a>), approximately 6‐fold (Figure <a href="#fcp70044-fig-0001" class="usa-link">1d</a>).</p>
<figure class="fig xbox font-sm" id="fcp70044-fig-0001"><h4 class="obj_head">FIGURE 1.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bc8a/12335911/9c32c8c5734d/FCP-39-0-g005.jpg" loading="lazy" id="jats-graphic-1" height="1180" width="669" alt="FIGURE 1"></p>
<div class="p text-right font-secondary"><a href="figure/fcp70044-fig-0001/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Acquired resistance to cisplatin can lead to altered expression of enzymes involved in glutamine metabolism. (a) Parental and cisplatin (CDDP)‐resistant cell line pairs were exposed to a CDDP titration (100, 31.6, 9.98, 3.17, 1.03, 0.32, 0.1, 0.03 μM) and cell viability measured after 3 days via resazurin reduction. Mean values of three independent experiments shown, each performed with technical duplicates. Error bars indicate SEM. (b) Schematic of glutamine metabolism. ASCT2, glutamine importer; GLS1 and 2, glutaminase 1 and 2; GS, glutamine synthetase; SLC7A11, cystine glutamate antiporter. (c) Immunoblot analysis of lysates prepared from parental and CDDP‐resistant pairs with the indicated antibodies. A representative cropped blot from two independent experiments shown. (d) Densitometry analysis of SLC7A11 protein abundance in the CDDP‐resistant cell lines plotted relative to their parental counterpart. Values from three (HCC4006 cell line pair) or two (A2780 cell line pair) independent experiments plotted, with mean and minimum/maximum values indicated. Ordinary one‐way ANOVA: **<em>p</em> &lt; 0.01; ns, not significant.</p></figcaption></figure></section><section id="fcp70044-sec-0018"><h3 class="pmc_sec_title">3.2. Acquired Resistance to Cisplatin Can Lead to Differential Sensitivity to Targeted Agents</h3>
<p>We next investigated the utility of treatment interventions to target the cisplatin‐resistant cancer cells, and focused on treatments targeting glutamine metabolism or downstream processes.</p>
<p>We began by evaluating the cell line panel for sensitivity to erastin, targeting SLC7A11 [<a href="#fcp70044-bib-0016" class="usa-link" aria-describedby="fcp70044-bib-0016">16</a>], and RSL‐3, identified as targeting the lipid peroxidase GPX4 [<a href="#fcp70044-bib-0017" class="usa-link" aria-describedby="fcp70044-bib-0017">17</a>] that functions downstream of SLC7A11, although it should be noted that the selectivity of RSL‐3 was recently called into question [<a href="#fcp70044-bib-0018" class="usa-link" aria-describedby="fcp70044-bib-0018">18</a>]. Regardless, these targeted agents induce ferroptosis, an iron‐dependent cell death mechanism with broad implications for overcoming therapy resistance [<a href="#fcp70044-bib-0019" class="usa-link" aria-describedby="fcp70044-bib-0019">19</a>]. We observed that the HCC4006 cisplatin‐resistant cell line was cross‐resistant to erastin and RSL‐3 (Figure <a href="#fcp70044-fig-0002" class="usa-link">2a–d</a>), while a slight increased sensitivity was observed in the A2780‐cisplatin resistant cell model (Figure <a href="#fcp70044-fig-0002" class="usa-link">2a–d</a>).</p>
<figure class="fig xbox font-sm" id="fcp70044-fig-0002"><h4 class="obj_head">FIGURE 2.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bc8a/12335911/b8533f4c3582/FCP-39-0-g003.jpg" loading="lazy" id="jats-graphic-3" height="795" width="709" alt="FIGURE 2"></p>
<div class="p text-right font-secondary"><a href="figure/fcp70044-fig-0002/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Cisplatin‐resistant cancer cells acquire differential sensitivity to ferroptosis inducers and to glutaminase inhibition. Parental and cisplatin (CDDP)‐resistant cell line pairs were exposed to a titration of the indicated compound (a,b, erastin; c,d, RSL‐3; e,f, CB‐839) and cell viability measured after 3 days via resazurin reduction, dose–response and area under the dose–response data shown. Mean values from 2 to 3 independent experiments (as indicated) plotted, with each experiment performed with technical duplicates. Error bars on dose–response data indicates SEM, box on area under dose–response data indicates mean and minimum/maximum. Ordinary one‐way ANOVA: *<em>p</em> &lt; 0.05; **<em>p</em> &lt; 0.01, ****<em>p</em> &lt; 0.0001; ns, not significant. Drug titrations used—erastin, HCC4006 pair: 10, 3.2, 1, 0.32, 0.1, 0.03, 0.01, 0.003 μM; erastin A2780 pair: 10, 5.19, 2.72, 1.36, 0.72, 0.37, 0.19, 0.1 μM; RSL‐3, HCC4006 pair: 1, 0.32, 0.1, 0.03, 0.01, 0.003, 0.001, 0.0003 μM; RSL‐3 A2780 pair: 1, 0.52, 0.27, 0.14, 0.07, 0.04, 0.02, 0.01 μM; CB‐839, HCC4006 pair: 10, 3.2, 1, 0.32, 0.1, 0.03, 0.01, 0.001; CB‐839, A2780 pair: 10, 3.2, 1, 0.32, 0.1, 0.03, 0.01, 0.003.</p></figcaption></figure><p>CB‐839 (telaglenastat) is a potent and selective, orally bioavailable GLS1 inhibitor in advanced clinical testing [<a href="#fcp70044-bib-0020" class="usa-link" aria-describedby="fcp70044-bib-0020">20</a>, <a href="#fcp70044-bib-0021" class="usa-link" aria-describedby="fcp70044-bib-0021">21</a>]. Treatment of the cell line panel with a titration of this compound revealed a striking sensitivity of the HCC4006 cisplatin‐resistant cancer cells, with the half maximal inhibitory concentration (IC<sub>50</sub>) value decreasing by several orders of magnitude compared to the parental counterpart (Figure <a href="#fcp70044-fig-0002" class="usa-link">2e,f</a>). In contrast, the A2780 cisplatin‐resistant cell model and parental counterpart showed no differential sensitivity (Figure <a href="#fcp70044-fig-0002" class="usa-link">2e,f</a>).</p>
<p>Taken together, these data demonstrate that acquired resistance to cisplatin in cancer cell models can result in differential sensitivity to targeted agents.</p></section><section id="fcp70044-sec-0019"><h3 class="pmc_sec_title">3.3. Acquired Resistance to Cisplatin Can Lead to Dependency on Extracellular Glutamine</h3>
<p>In search of a common vulnerability of cisplatin‐resistant cancer cells, we next interrogated whether these cells had increased dependence upon glutamine, given the altered expression of glutamine metabolic enzymes we had observed (Figure <a href="#fcp70044-fig-0001" class="usa-link">1c,d</a>). We plated cells in complete medium in the presence or absence of glutamine and, following 2 days, measured the remaining viable cells. While the parental HCC4006 cells showed no dependence upon extracellular glutamine, their cisplatin‐resistant derivative did show significantly more dependence upon this amino acid for proliferation (Figure <a href="#fcp70044-fig-0003" class="usa-link">3a</a>). In contrast, both the parental and cisplatin‐resistant A2780 cells were equally dependent upon extracellular glutamine for proliferation. We recapitulated both these results in colony outgrowth assays performed in the presence or absence of glutamine (Figure <a href="#fcp70044-fig-0003" class="usa-link">3b,c</a>).</p>
<figure class="fig xbox font-sm" id="fcp70044-fig-0003"><h4 class="obj_head">FIGURE 3.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bc8a/12335911/792e7b9e4959/FCP-39-0-g004.jpg" loading="lazy" id="jats-graphic-5" height="1075" width="669" alt="FIGURE 3"></p>
<div class="p text-right font-secondary"><a href="figure/fcp70044-fig-0003/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Acquired resistance to cisplatin can lead to a dependency upon extracellular glutamine in cell line models. (a) Parental and cisplatin (CDDP)‐resistant cell line pairs were cultured in complete media or media lacking glutamine (Gln –) for 2 days prior to resazurin reduction assay. Proportion of viable cells in the absence of glutamine relative to cells cultured in complete media (dashed line) plotted. Mean values from three independent experiments shown with each experiment performed with a minimum of six technical replicates. Bars and error bars indicate mean and SEM. Unpaired two‐tailed <em>t</em> test: *<em>p</em> &lt; 0.05; ns, not significant. (b,c) Parental and CDDP‐resistant cell line pairs were cultured in complete media (Gln +) or media lacking glutamine (Gln –) in a colony outgrowth assay before fixation and staining. Representative images shown in (b) and surviving fraction relative to complete media control (dashed line) plotted in (c). Mean values from four independent experiments shown with each experiment performed with technical duplicates. Bars and error bars indicate mean and SEM. Unpaired two‐tailed <em>t</em> test: **<em>p</em> &lt; 0.01; ns, not significant.</p></figcaption></figure><p>Seeking to understand the mechanistic basis of glutamine dependence, specifically in the HCC4006 cisplatin‐resistant model, we speculated it could be due to up‐regulation of the glutamate‐cystine antiporter SLC7A11 (Figure <a href="#fcp70044-fig-0001" class="usa-link">1c,d</a>). Thus, in the HCC4006 cisplatin‐resistant cell model, we depleted SLC7A11 protein using siRNA, confirmed by immunoblot analysis (Figure <a href="#fcp70044-fig-0004" class="usa-link">4a</a>), and subjected these cells to glutamine‐withdrawal before measuring remaining viable cells with orthogonal readouts. We observed that depletion of SLC7A11 partially reduced the glutamine‐dependence of the cisplatin‐resistant cancer model (Figure <a href="#fcp70044-fig-0004" class="usa-link">4b,c</a>), supporting that up‐regulation of SLC7A11 contributes to glutamine dependency. We next assessed the prognostic value of SLC7A11 expression in clinical lung and ovarian cancer cohorts, each comprising substantial numbers of cases with both low and high expression levels. SLC7A11 expression was significantly associated with poorer overall survival in lung cancer but showed no prognostic relevance in ovarian cancer (Figure <a href="#fcp70044-fig-0004" class="usa-link">4d</a>, Figure <a href="#fcp70044-supitem-0001" class="usa-link">S1</a>).</p>
<figure class="fig xbox font-sm" id="fcp70044-fig-0004"><h4 class="obj_head">FIGURE 4.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bc8a/12335911/4fea8cbe02cd/FCP-39-0-g002.jpg" loading="lazy" id="jats-graphic-7" height="500" width="709" alt="FIGURE 4"></p>
<div class="p text-right font-secondary"><a href="figure/fcp70044-fig-0004/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>SLC7A11 expression contributes to glutamine dependence of cisplatin‐resistant lung adenocarcinoma cell model and correlates with overall survival in this malignancy. (a) HCC4006 cisplatin (CDDP)‐resistant cells were transfected with control (si‐Neg) or SLC7A11 targeting (si‐SLC7A11) siRNA and after 3 days, lysates prepared and analyzed by immunoblot with the indicated antibodies. A representative cropped blot from four independent experiments shown. (b) Cells as transfected in (a) were cultured in complete media or media lacking glutamine (Gln –) for 2 days before resazurin reduction assay. Proportion of viable cells in the absence of glutamine relative to cells cultured in complete media (dashed line) plotted. Mean values from four independent experiments shown with each experiment performed with a minimum of six technical replicates. Bars and error bars indicate mean and SEM. Unpaired two‐tailed <em>t</em> test: **<em>p</em> &lt; 0.01. (c) Cells as transfected in (a) were cultured in complete media (Gln +) or media lacking glutamine (Gln –) in a colony outgrowth assay before fixation and staining. Representative images shown from two independent experiments shown. (d) Kaplan–Meier survival analysis was performed using the GEPIA platform for lung adenocarcinoma (LUAD) and ovarian serous cystadenocarcinoma (OV), stratifying patients by median <em>SLC7A11</em> expression (TPM, transcript per million). In LUAD (<em>n</em> = 478), high <em>SLC7A11</em> expression was associated with significantly worse overall survival (log‐rank <em>p</em> = 0.036; hazard ratio [HR] = 1.4; <em>p</em> (HR) = 0.037). In contrast, in OV (<em>n</em> = 421), <em>SLC7A11</em> expression was not significantly associated with survival (log‐rank <em>p</em> = 0.11; HR = 0.82; <em>p</em> (HR) = 0.11).</p></figcaption></figure></section><section id="fcp70044-sec-0020"><h3 class="pmc_sec_title">3.4. Acquired Resistance to Cisplatin Can Lead to Increased Sensitivity to ASNase</h3>
<p>Next, we evaluated the decades‐old anti‐leukemic therapy ASNase as a potential approach to target cisplatin‐resistant cancer cells. The clinical use of ASNase centers upon the enzymatic hydrolysis of extracellular asparagine, required for the proliferation of asparagine auxotroph leukemic cells, but ASNase also possesses glutaminase activity, and accordingly enzymatically depletes extracellular glutamine [<a href="#fcp70044-bib-0022" class="usa-link" aria-describedby="fcp70044-bib-0022">22</a>, <a href="#fcp70044-bib-0023" class="usa-link" aria-describedby="fcp70044-bib-0023">23</a>]. Here, we interrogated the ability of ASNase to target cisplatin‐resistant cancer cells. Supplementation of cell medium with ASNase reduced the proportion of viable cells in a dose‐dependent manner in colony outgrowth assays (Figure <a href="#fcp70044-fig-0005" class="usa-link">5a,b</a>). Notably, both cisplatin‐resistant models showed elevated sensitivity compared to their parental counterparts, with the glutamine‐dependent HCC4006 cisplatin‐resistant model being the most sensitive (Figure <a href="#fcp70044-fig-0005" class="usa-link">5a–c</a>).</p>
<figure class="fig xbox font-sm" id="fcp70044-fig-0005"><h4 class="obj_head">FIGURE 5.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bc8a/12335911/6fac44c774cf/FCP-39-0-g001.jpg" loading="lazy" id="jats-graphic-9" height="850" width="709" alt="FIGURE 5"></p>
<div class="p text-right font-secondary"><a href="figure/fcp70044-fig-0005/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Cisplatin‐resistant cancer cells are sensitive to ASNase. (a,b) Parental and cisplatin (CDDP)‐resistant cell line pairs were cultured in complete media or media supplemented with asparaginase (ASNase; 0.3 or 0.1 U/mL) in a colony outgrowth assay, with drug supplementation replaced every 3–4 days, before fixation and staining. Representative images shown together with plot of surviving fraction relative to untreated control. Mean values from three independent experiments shown with each experiment performed with technical duplicates. Bars and error bars indicate mean and SEM. Unpaired two‐tailed <em>t</em> test comparing the parental and CDDP‐resistant cell line at each ASNase dose: *<em>p</em> &lt; 0.05; **<em>p</em> &lt; 0.01; ns, not significant. (c) Area under the dose–response data derived from (a,b). Mean values from three independent experiments, each performed with technical duplicates, shown; box indicates mean and minimum/maximum. Ordinary one‐way ANOVA: **<em>p</em> &lt; 0.01.</p></figcaption></figure></section><section id="fcp70044-sec-0021"><h3 class="pmc_sec_title">3.5. ASNase and Cisplatin Combine in an Additive Manner in Cisplatin‐Resistant Cancer Cells</h3>
<p>Given ASNase is a cancer therapy in routine clinical practice and successfully targeted both cisplatin‐resistant cell models, we next sought to evaluate the applicability of this approach further and test whether it can be successfully combined with cisplatin therapy. We speculated that enzymatic depletion of extracellular glutamine by ASNase may re‐sensitize the cisplatin‐resistant cells to cisplatin. To assess this combination in depth, we seeded the cisplatin‐resistant HCC4006 and A2780 cancer cells upon dose matrices of cisplatin and ASNase and measured cell viability following a 3‐day treatment. ASNase dose‐dependently decreased the proportion of viable cells in combination with cisplatin (Figure <a href="#fcp70044-fig-0006" class="usa-link">6a,b</a>). The ability of ASNase to sensitize cells to cisplatin was noted in both A2780 and HCC4006 cisplatin‐resistant models, though more prominent in the glutamine‐dependent HCC4006 model (Figure <a href="#fcp70044-fig-0006" class="usa-link">6a,b</a>). We next used the data generated to assess the drug combination effect over the entire drug matrix by several synergy models, which overall showed the combination to be largely additive, with weak synergy observed with one synergy metric (Figure <a href="#fcp70044-fig-0006" class="usa-link">6c</a>). Inspection of the dose–response landscapes revealed a peak of synergy between ASNase and cisplatin in the HCC4006 cisplatin‐resistant model at select drug doses, which was absent in the A2780 cisplatin‐resistant model (Figure <a href="#fcp70044-fig-0006" class="usa-link">6d</a>). Overall, these data support that ASNase can be combined with cisplatin to target cisplatin‐resistant cancer cells.</p>
<figure class="fig xbox font-sm" id="fcp70044-fig-0006"><h4 class="obj_head">FIGURE 6.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bc8a/12335911/491b765efbf7/FCP-39-0-g006.jpg" loading="lazy" id="jats-graphic-11" height="1030" width="709" alt="FIGURE 6"></p>
<div class="p text-right font-secondary"><a href="figure/fcp70044-fig-0006/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>ASNase and cisplatin combination treatment in cisplatin‐resistant cancer cells results in additive inhibition of growth. (a) Cisplatin (CDDP)‐resistant cell lines were exposed to a CDDP (100, 32, 10, 3, 1 μM) vs. asparaginase (ASNase, 1, 0.3, 0.1 U/mL) dose matrix and cell viability measured after 3 days via resazurin reduction. Mean value from three independent experiments shown, each experiment performed with technical duplicates. Error bars indicate SEM. (b) CDDP area under the dose–response (AUC) as a function of ASNase concentration, derived from the data in (a). (c) Drug synergy plot for CDDP and ASNase combination in the indicated cell line with the indicated synergy model. Data derived from proliferation inhibition values in (a). Each dose–response matrix experiment was performed with technical duplicates and the mean values used to calculate the dose–response landscape from which the average synergy score derived. Data from three independent experiments shown, error bars indicate SEM. (d) Average synergy landscapes for the indicated cell lines shown using the ZIP synergy model, derived from data in (a).</p></figcaption></figure></section></section><section id="fcp70044-sec-0022"><h2 class="pmc_sec_title">4. Discussion</h2>
<p>Despite many advances in treatment modalities, cisplatin‐containing chemotherapy regimens remain widely deployed in the treatment of solid malignancies. One of the main clinical limitations of this therapeutic agent is resistance. Thus, efforts are needed to identify treatment strategies to target cisplatin‐resistant cells. In the present study, we used cancer cell line pairs with acquired resistance to cisplatin, derived from a different solid malignancy in which cisplatin‐based therapy is used (lung and ovarian cancer). Using these models, we observed that acquired resistance to cisplatin can lead to altered expression of glutamine metabolic enzymes and differential sensitivity to targeted agents. We show that cisplatin‐resistant cancer cells can be dependent upon extracellular glutamine and subsequently identified ASNase therapy as a potential actionable strategy to target these cells.</p>
<p>Metabolic plasticity is a hallmark of cancer that is readily exploited in the acquirement of drug resistance, but this can also lead to collateral vulnerabilities of these drug‐resistant cells. In the case of acquired resistance to platinum therapy, rewiring of glutamine metabolism can lead to a dependence upon extracellular glutamine, which has been previously documented in cell models [<a href="#fcp70044-bib-0024" class="usa-link" aria-describedby="fcp70044-bib-0024">24</a>, <a href="#fcp70044-bib-0025" class="usa-link" aria-describedby="fcp70044-bib-0025">25</a>, <a href="#fcp70044-bib-0026" class="usa-link" aria-describedby="fcp70044-bib-0026">26</a>, <a href="#fcp70044-bib-0027" class="usa-link" aria-describedby="fcp70044-bib-0027">27</a>, <a href="#fcp70044-bib-0028" class="usa-link" aria-describedby="fcp70044-bib-0028">28</a>, <a href="#fcp70044-bib-0029" class="usa-link" aria-describedby="fcp70044-bib-0029">29</a>, <a href="#fcp70044-bib-0030" class="usa-link" aria-describedby="fcp70044-bib-0030">30</a>]. Furthermore, cisplatin‐resistant tumors grafted in mice have also been shown to be selectively sensitive to nutrient deprivation through repeated fasting cycles compared to cisplatin‐sensitive tumors [<a href="#fcp70044-bib-0026" class="usa-link" aria-describedby="fcp70044-bib-0026">26</a>], and high GLS1 expression has been correlated with reduced survival of ovarian cancer patients in several independent cohorts [<a href="#fcp70044-bib-0024" class="usa-link" aria-describedby="fcp70044-bib-0024">24</a>]. Here, we show that a cisplatin‐resistant experimental model, the lung HCC4006 cell line, also acquired dependence upon extracellular glutamine to sustain cell proliferation. This glutamine addiction could be mechanistically linked to up‐regulation of the glutamate‐cystine antiporter SLC7A11, as SLC7A11 protein level was higher in this model and depletion via siRNA could reduce the dependence upon extracellular glutamine. This mechanism is distinct from previous reports documenting glutamine addiction in cisplatin‐resistant cell models, which thus far have been attributed to elevated expression of ASCT2 and/or GLS1 [<a href="#fcp70044-bib-0024" class="usa-link" aria-describedby="fcp70044-bib-0024">24</a>, <a href="#fcp70044-bib-0028" class="usa-link" aria-describedby="fcp70044-bib-0028">28</a>, <a href="#fcp70044-bib-0030" class="usa-link" aria-describedby="fcp70044-bib-0030">30</a>], and promoter methylation‐mediated downregulation of GS [<a href="#fcp70044-bib-0025" class="usa-link" aria-describedby="fcp70044-bib-0025">25</a>].</p>
<p>Elevated SLC7A11 has been documented in cisplatin‐resistant cell lines [<a href="#fcp70044-bib-0027" class="usa-link" aria-describedby="fcp70044-bib-0027">27</a>, <a href="#fcp70044-bib-0031" class="usa-link" aria-describedby="fcp70044-bib-0031">31</a>, <a href="#fcp70044-bib-0032" class="usa-link" aria-describedby="fcp70044-bib-0032">32</a>, <a href="#fcp70044-bib-0033" class="usa-link" aria-describedby="fcp70044-bib-0033">33</a>], patient‐derived material ex vivo [<a href="#fcp70044-bib-0034" class="usa-link" aria-describedby="fcp70044-bib-0034">34</a>], and tumors in vivo [<a href="#fcp70044-bib-0032" class="usa-link" aria-describedby="fcp70044-bib-0032">32</a>, <a href="#fcp70044-bib-0033" class="usa-link" aria-describedby="fcp70044-bib-0033">33</a>], and in experiments in pre‐clinical models, has been demonstrated to contribute to cisplatin resistance via RNAi or targeting with small molecules [<a href="#fcp70044-bib-0027" class="usa-link" aria-describedby="fcp70044-bib-0027">27</a>, <a href="#fcp70044-bib-0031" class="usa-link" aria-describedby="fcp70044-bib-0031">31</a>, <a href="#fcp70044-bib-0032" class="usa-link" aria-describedby="fcp70044-bib-0032">32</a>, <a href="#fcp70044-bib-0033" class="usa-link" aria-describedby="fcp70044-bib-0033">33</a>]. Furthermore, in the case of bladder cancer [<a href="#fcp70044-bib-0032" class="usa-link" aria-describedby="fcp70044-bib-0032">32</a>] and gastric cancer [<a href="#fcp70044-bib-0033" class="usa-link" aria-describedby="fcp70044-bib-0033">33</a>], high SLC7A11 expression correlates with poorer survival in cisplatin‐treated patients. In our study, we identify high SLC7A11 expression to significantly associate with poorer overall survival in lung but not ovarian cancer. We hypothesize that the elevated expression of SLC7A11 we observe in our model seeks to fuel GSH biosynthesis, to facilitate cisplatin resistance, which is consistent with earlier studies [<a href="#fcp70044-bib-0027" class="usa-link" aria-describedby="fcp70044-bib-0027">27</a>, <a href="#fcp70044-bib-0031" class="usa-link" aria-describedby="fcp70044-bib-0031">31</a>, <a href="#fcp70044-bib-0032" class="usa-link" aria-describedby="fcp70044-bib-0032">32</a>, <a href="#fcp70044-bib-0033" class="usa-link" aria-describedby="fcp70044-bib-0033">33</a>]. But a consequence of increased cystine import to fuel GSH biosynthesis is increased glutamate export, which in turn renders this cell model dependent upon glutamine. This is also supported by literature outside the context of chemoresistance that has shown that SLC7A11 can dictate glutamine dependence in cell models [<a href="#fcp70044-bib-0035" class="usa-link" aria-describedby="fcp70044-bib-0035">35</a>, <a href="#fcp70044-bib-0036" class="usa-link" aria-describedby="fcp70044-bib-0036">36</a>, <a href="#fcp70044-bib-0037" class="usa-link" aria-describedby="fcp70044-bib-0037">37</a>, <a href="#fcp70044-bib-0038" class="usa-link" aria-describedby="fcp70044-bib-0038">38</a>], and is supported in our study by the hypersensitivity of HCC4006 cisplatin‐resistant cells, with high SLC7A11 expression, to GLS1 inhibitor CB‐839, which indicates the elevated demand for glutamine is to generate glutamate. With regard to the A2780 cisplatin‐resistant model, although we observed reduced expression of GS, as previously reported [<a href="#fcp70044-bib-0025" class="usa-link" aria-describedby="fcp70044-bib-0025">25</a>], we did not see increased dependence of this model upon glutamine for cell proliferation. Instead, we observed that both the parental cell line and the cisplatin‐resistant derivative equally required glutamine for proliferation. The underlying mechanism in this case remains unclear.</p>
<p>In this study, we sought therapeutic approaches to target cisplatin‐resistant cells. Up‐regulation of a target can have differential effects upon cell killing through pharmacological inhibition of that same target. For instance, up‐regulation can indicate increased dependence of cells and thus enhanced sensitivity, or conversely, up‐regulation can also result in therapy resistance, given the higher levels of the target to be inhibited. We first evaluated experimental molecules known to induce ferroptosis that directly target SLC7A11 or downstream processes, as SLC7A11 was up‐regulated in the HCC4006 cisplatin‐resistant model. We observed that these cells became cross‐resistant to ferroptosis inducers erastin and RSL‐3, consistent with over‐expression studies outside the context of chemoresistance [<a href="#fcp70044-bib-0039" class="usa-link" aria-describedby="fcp70044-bib-0039">39</a>, <a href="#fcp70044-bib-0040" class="usa-link" aria-describedby="fcp70044-bib-0040">40</a>], likely reflecting increased intracellular GSH levels, mediated by elevated SLC7A11, that would buffer against ferroptotic cell death. Altogether, these data indicate exploiting ferroptosis, and specifically SLC7A11 in cells with high SLC7A11 expression, as a means to kill cisplatin‐resistant cells may not be a viable strategy. However, in the A2780 cisplatin‐resistant model that did not up‐regulate SLC7A11, these agents were slightly more effective. Next, we evaluated the GLS1 allosteric inhibitor CB‐839 (telaglenastat) and observed striking sensitivity in specifically the HCC4006 cisplatin‐resistant model with high SLC7A11 expression, consistent with an earlier report demonstrating SLC7A11 activity can drive CB‐839 sensitivity [<a href="#fcp70044-bib-0036" class="usa-link" aria-describedby="fcp70044-bib-0036">36</a>]. This highlights a promising context to further investigate the use of this molecule, particularly in lung cancer in which we observed high SLC7A11 expression significantly associates with worse overall survival. In contrast, the A2780 cisplatin‐resistant line showed no significant difference in CB‐839 sensitivity compared to its parental counterpart. Altogether, these data highlight the difficulty in finding agents to robustly target cancer cells with acquired resistance to cisplatin.</p>
<p>ASNase is a clinically approved therapy which was the first to exploit a metabolic dependency in cancer cells, specifically the dependence of acute lymphoblastic leukemia (ALL) cells upon circulating asparagine. Here, we observed that cisplatin‐resistant cancer cells are more sensitive to ASNase, and unlike the targeted ferroptosis inducers and glutaminase inhibitor, ASNase sensitivity was consistent between the cisplatin‐resistant models, although elevated in the glutamine‐dependent HCC4006 model. Furthermore, ASNase appeared to re‐sensitize these models to cisplatin. We speculate the reason for this is that ASNase also possesses glutaminase activity and can thus deplete both asparagine and glutamine, which has been documented in plasma [<a href="#fcp70044-bib-0022" class="usa-link" aria-describedby="fcp70044-bib-0022">22</a>, <a href="#fcp70044-bib-0023" class="usa-link" aria-describedby="fcp70044-bib-0023">23</a>]. We hypothesize the enzymatic depletion of glutamine would stifle GSH production, required to detoxify aquated cisplatin. The glutaminase activity may also be the reason for enhanced monotherapy sensitivity in the glutamine‐addicted HCC4006 model and potentially highlights the utility of elevated SLC7A11 expression in predicting response. However, given ASNase monotherapy was more effective in both cisplatin‐resistant models compared to parental counterparts—including the A2780 model which was not more dependent upon glutamine—this implies cisplatin‐resistant cells may have increased reliance upon extracellular asparagine also. There is precedent for cancer cells outside of ALL to have dependency upon asparagine, which can arise by multiple mechanisms [<a href="#fcp70044-bib-0041" class="usa-link" aria-describedby="fcp70044-bib-0041">41</a>]. The precise mechanism in this case remains to be investigated.</p>
<p>Outside the context of chemoresistance, there are several examples of exploiting the glutaminase activity of ASNase for targeting glutamine‐dependent cancer cells, including both solid [<a href="#fcp70044-bib-0035" class="usa-link" aria-describedby="fcp70044-bib-0035">35</a>, <a href="#fcp70044-bib-0042" class="usa-link" aria-describedby="fcp70044-bib-0042">42</a>] and hematological cancer‐derived models [<a href="#fcp70044-bib-0043" class="usa-link" aria-describedby="fcp70044-bib-0043">43</a>, <a href="#fcp70044-bib-0044" class="usa-link" aria-describedby="fcp70044-bib-0044">44</a>, <a href="#fcp70044-bib-0045" class="usa-link" aria-describedby="fcp70044-bib-0045">45</a>]. Although glutamine is highly abundant in plasma [<a href="#fcp70044-bib-0009" class="usa-link" aria-describedby="fcp70044-bib-0009">9</a>], ASNase therapy can substantially deplete the level of this amino acid [<a href="#fcp70044-bib-0023" class="usa-link" aria-describedby="fcp70044-bib-0023">23</a>], and the glutaminase activity of ASNase is understood to contribute to the anti‐leukemic activity but is also considered to be a source of toxicity [<a href="#fcp70044-bib-0023" class="usa-link" aria-describedby="fcp70044-bib-0023">23</a>], and deciphering the relative contributions is an active area of research [<a href="#fcp70044-bib-0046" class="usa-link" aria-describedby="fcp70044-bib-0046">46</a>]. This could be one note of caution with regards to the repurposing of ASNase therapy against solid malignancies, particularly in adults. While ASNase therapy is routinely deployed successfully in the treatment of children with ALL, toxicities in adults can be limiting, and this has been observed in several trials against solid malignancies [<a href="#fcp70044-bib-0047" class="usa-link" aria-describedby="fcp70044-bib-0047">47</a>, <a href="#fcp70044-bib-0048" class="usa-link" aria-describedby="fcp70044-bib-0048">48</a>]. Thus, studies to understand and overcome these limitations of ASNase therapy in solid malignancies are an ongoing research area [<a href="#fcp70044-bib-0049" class="usa-link" aria-describedby="fcp70044-bib-0049">49</a>, <a href="#fcp70044-bib-0050" class="usa-link" aria-describedby="fcp70044-bib-0050">50</a>]. Nevertheless, repurposing ASNase therapy or the development of a specific glutaminase therapy [<a href="#fcp70044-bib-0051" class="usa-link" aria-describedby="fcp70044-bib-0051">51</a>, <a href="#fcp70044-bib-0052" class="usa-link" aria-describedby="fcp70044-bib-0052">52</a>] to exploit glutamine addiction and/or re‐sensitize to cisplatin could be a promising approach. It should be noted that, relevant to the combination of ASNase with cisplatin resulting in an additive inhibition of proliferation in the cisplatin‐resistant models in our study, additive drug combinations can be curative [<a href="#fcp70044-bib-0053" class="usa-link" aria-describedby="fcp70044-bib-0053">53</a>].</p></section><section id="fcp70044-sec-0023"><h2 class="pmc_sec_title">5. Conclusion</h2>
<p>In conclusion, in the present study, we provide evidence that repurposing of the decades‐old anti‐leukemic therapy ASNase could be a promising approach to target cisplatin‐resistant cells and possibly re‐sensitize to cisplatin. An important limitation of our study is the small number of cell models characterized, and future studies should expand upon this together with interrogating more complex pre‐clinical models of chemoresistance.</p></section><section id="fcp70044-sec-0024"><h2 class="pmc_sec_title">Author Contributions</h2>
<p>Conceptualization: Jiantao Wang and Sean G Rudd. Methodology: Jiantao Wang, Nasim Pouryaghoub, Robert Strauss, Jiri Bartek, Si Min Zhang and Sean G Rudd. Investigation: Jiantao Wang, Nasim Pouryaghoub, Robert Strauss, Jiri Bartek, Si Min Zhang and Sean G Rudd. Writing – original draft: Jiantao Wang and Sean G Rudd. Writing – reviewing and editing: Jiantao Wang, Jiri Bartek, Si Min Zhang, and Sean G Rudd. Visualization: Jiantao Wang, Robert Strauss, Si Min Zhang, and Sean G Rudd. Resources: Robert Strauss and Jiri Bartek. Funding acquisition: Jiri Bartek and Sean G Rudd. Supervision: Jiri Bartek, Si Min Zhang, and Sean G Rudd.</p></section><section id="fcp70044-sec-0026"><h2 class="pmc_sec_title">Conflicts of Interest</h2>
<p>The authors declare no conflicts of interest.</p></section><section id="sec26"><h2 class="pmc_sec_title">Supporting information</h2>
<section class="sm xbox font-sm" id="fcp70044-supitem-0001"><div class="caption p"><p>
<strong>Figure S1:</strong> Kaplan–Meier survival analyses were performed using the KM‐plotter platform for lung and ovarian cancer—as detailed in Materials and Methods—stratifying patients by median <em>SLC7A11</em> expression. In lung cancer (<em>n</em> = 2166), high <em>SLC7A11</em> expression was associated with significantly worse overall survival (log‐rank <em>p</em> = 0.019; hazard ratio [HR] = 1.15). In contrast, in ovarian cancer (<em>n</em> = 1435), SLC7A11 expression was not significantly associated with survival (log‐rank <em>p</em> = 0.27; HR = 0.93).</p></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/12335911/bin/FCP-39-0-s001.pdf" data-ga-action="click_feat_suppl" class="usa-link">FCP-39-0-s001.pdf</a><sup> (658.8KB, pdf) </sup>
</div></div></section></section><section id="fcp70044-sec-0025" class="ack"><h2 class="pmc_sec_title">Acknowledgments</h2>
<p>We would like to thank Femke M. Hormann for critical reading of the manuscript together with Sophia Cedar and Klas Wiman for sharing reagents for pilot studies.</p></section><section id="notes1"><p>

Wang J., Pouryaghoub N., Strauss R., Bartek J., Zhang S., and Rudd S., “Repurposing Asparaginase Therapy to Target Cisplatin‐Resistant Cancer Cells,” Fundamental &amp; Clinical Pharmacology
39, no. 5 (2025): e70044, 10.1111/fcp.70044.
</p>
<section id="fcp70044-ntgp-0001" class="fn-group"><div class="fn-group p font-secondary-light font-sm"><div class="fn p" id="fcp70044-note-0001"><p>
<strong>Funding:</strong> This work was supported by the Swedish Research Council (VR‐MH 2014‐46602‐117891‐30 to J.B. and 2018‐02114 to S.G.R), the Swedish Cancer Society (19‐0056‐JIA, 20‐0879‐Pj, and 23‐2782‐Pj to S.G.R), the Swedish Childhood Cancer Foundation (PR2019‐0014 and PR2022‐0003 to S.G.R), the Danish Cancer Society (R322‐A17482 to J.B.), the Fabrikant Chas. Otzen's Fond and Købmand Niels Erik Munk Pedersen Fonden (both foundations providing the OVACAN grant to J.B. and R.S.) the Talent Training Funding for overseas study of West China Hospital, Sichuan University (to J.W.), Åke Wibergs Foundation (M22‐0011 and M23‐0088 to S.M.Z.), Stiftelsen Clas Groschinskys Minnesfond (M2353 and M2449 to S.M.Z.) and Karolinska Institutet in the form of a Board of Research Faculty Funded Career Position (to S.G.R).</p></div></div></section></section><section id="fcp70044-sec-0028"><h2 class="pmc_sec_title">Data Availability Statement</h2>
<p>Data can be made available by the authors upon request.</p></section><section id="fcp70044-bibl-0001" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="fcp70044-bibl-0001_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="fcp70044-bib-0001">
<span class="label">1.</span><cite>
Rudd S. G., “Targeting Pan‐Essential Pathways in Cancer With Cytotoxic Chemotherapy: Challenges and Opportunities,” Cancer Chemotherapy and Pharmacology
92, no. 4 (2023): 241–251, 10.1007/s00280-023-04562-3.
</cite> [<a href="https://doi.org/10.1007/s00280-023-04562-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10435635/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37452860/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Chemotherapy%20and%20Pharmacology&amp;title=Targeting%20Pan%E2%80%90Essential%20Pathways%20in%20Cancer%20With%20Cytotoxic%20Chemotherapy:%20Challenges%20and%20Opportunities&amp;author=S.%20G.%20Rudd&amp;volume=92&amp;issue=4&amp;publication_year=2023&amp;pages=241-251&amp;pmid=37452860&amp;doi=10.1007/s00280-023-04562-3&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70044-bib-0002">
<span class="label">2.</span><cite>
Romani A. M. P., “Cisplatin in Cancer Treatment,” Biochemical Pharmacology
206 (2022): 115323, 10.1016/j.bcp.2022.115323.
</cite> [<a href="https://doi.org/10.1016/j.bcp.2022.115323" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36368406/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biochemical%20Pharmacology&amp;title=Cisplatin%20in%20Cancer%20Treatment&amp;author=A.%20M.%20P.%20Romani&amp;volume=206&amp;publication_year=2022&amp;pages=115323&amp;pmid=36368406&amp;doi=10.1016/j.bcp.2022.115323&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70044-bib-0003">
<span class="label">3.</span><cite>
Wang D. and Lippard S. J., “Cellular Processing of Platinum Anticancer Drugs,” Nature Reviews. Drug Discovery
4, no. 4 (2005): 307–320, 10.1038/nrd1691.
</cite> [<a href="https://doi.org/10.1038/nrd1691" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15789122/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Reviews.%20Drug%20Discovery&amp;title=Cellular%20Processing%20of%20Platinum%20Anticancer%20Drugs&amp;author=D.%20Wang&amp;author=S.%20J.%20Lippard&amp;volume=4&amp;issue=4&amp;publication_year=2005&amp;pages=307-320&amp;pmid=15789122&amp;doi=10.1038/nrd1691&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70044-bib-0004">
<span class="label">4.</span><cite>
Deans A. J. and West S. C., “DNA Interstrand Crosslink Repair and Cancer,” Nature Reviews Cancer
11, no. 7 (2011): 467–480, 10.1038/nrc3088.
</cite> [<a href="https://doi.org/10.1038/nrc3088" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3560328/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21701511/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Reviews%20Cancer&amp;title=DNA%20Interstrand%20Crosslink%20Repair%20and%20Cancer&amp;author=A.%20J.%20Deans&amp;author=S.%20C.%20West&amp;volume=11&amp;issue=7&amp;publication_year=2011&amp;pages=467-480&amp;pmid=21701511&amp;doi=10.1038/nrc3088&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70044-bib-0005">
<span class="label">5.</span><cite>
Galluzzi L., Vitale I., Michels J., et al., “Systems Biology of Cisplatin Resistance: Past, Present and Future,” Cell Death &amp; Disease
5, no. 5 (2014): e1257, 10.1038/cddis.2013.428.
</cite> [<a href="https://doi.org/10.1038/cddis.2013.428" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4047912/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24874729/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cell%20Death%20&amp;%20Disease&amp;title=Systems%20Biology%20of%20Cisplatin%20Resistance:%20Past,%20Present%20and%20Future&amp;author=L.%20Galluzzi&amp;author=I.%20Vitale&amp;author=J.%20Michels&amp;volume=5&amp;issue=5&amp;publication_year=2014&amp;pages=e1257&amp;pmid=24874729&amp;doi=10.1038/cddis.2013.428&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70044-bib-0006">
<span class="label">6.</span><cite>
Galluzzi L., Senovilla L., Vitale I., et al., “Molecular mechanisms of cisplatin resistance,” Oncogene
31, no. 15 (2012): 1869–1883, 10.1038/onc.2011.384.
</cite> [<a href="https://doi.org/10.1038/onc.2011.384" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21892204/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncogene&amp;title=Molecular%20mechanisms%20of%20cisplatin%20resistance&amp;author=L.%20Galluzzi&amp;author=L.%20Senovilla&amp;author=I.%20Vitale&amp;volume=31&amp;issue=15&amp;publication_year=2012&amp;pages=1869-1883&amp;pmid=21892204&amp;doi=10.1038/onc.2011.384&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70044-bib-0007">
<span class="label">7.</span><cite>
Rottenberg S., Disler C., and Perego P., “The Rediscovery of Platinum‐Based Cancer Therapy,” Nature Reviews. Cancer
21, no. 1 (2021): 37–50, 10.1038/s41568-020-00308-y.
</cite> [<a href="https://doi.org/10.1038/s41568-020-00308-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33128031/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Reviews.%20Cancer&amp;title=The%20Rediscovery%20of%20Platinum%E2%80%90Based%20Cancer%20Therapy&amp;author=S.%20Rottenberg&amp;author=C.%20Disler&amp;author=P.%20Perego&amp;volume=21&amp;issue=1&amp;publication_year=2021&amp;pages=37-50&amp;pmid=33128031&amp;doi=10.1038/s41568-020-00308-y&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70044-bib-0008">
<span class="label">8.</span><cite>
Bansal A. and Simon M. C., “Glutathione Metabolism in Cancer Progression and Treatment Resistance,” Journal of Cell Biology
217, no. 7 (2018): 2291–2298, 10.1083/jcb.201804161.
</cite> [<a href="https://doi.org/10.1083/jcb.201804161" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6028537/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29915025/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Cell%20Biology&amp;title=Glutathione%20Metabolism%20in%20Cancer%20Progression%20and%20Treatment%20Resistance&amp;author=A.%20Bansal&amp;author=M.%20C.%20Simon&amp;volume=217&amp;issue=7&amp;publication_year=2018&amp;pages=2291-2298&amp;pmid=29915025&amp;doi=10.1083/jcb.201804161&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70044-bib-0009">
<span class="label">9.</span><cite>
Yang L., Venneti S., and Nagrath D., “Glutaminolysis: A Hallmark of Cancer Metabolism,” Annual Review of Biomedical Engineering
19 (2017): 163–194, 10.1146/annurev-bioeng-071516-044546.</cite> [<a href="https://doi.org/10.1146/annurev-bioeng-071516-044546" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28301735/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Annual%20Review%20of%20Biomedical%20Engineering&amp;title=Glutaminolysis:%20A%20Hallmark%20of%20Cancer%20Metabolism&amp;author=L.%20Yang&amp;author=S.%20Venneti&amp;author=D.%20Nagrath&amp;volume=19&amp;publication_year=2017&amp;pages=163-194&amp;pmid=28301735&amp;doi=10.1146/annurev-bioeng-071516-044546&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70044-bib-0010">
<span class="label">10.</span><cite>
Mäkelä P., Zhang S. M., and Rudd S. G., “Drug Synergy Scoring Using Minimal Dose Response Matrices,” BMC Research Notes
14, no. 1 (2021): 27, 10.1186/s13104-021-05445-7.
</cite> [<a href="https://doi.org/10.1186/s13104-021-05445-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7816329/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33468238/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMC%20Research%20Notes&amp;title=Drug%20Synergy%20Scoring%20Using%20Minimal%20Dose%20Response%20Matrices&amp;author=P.%20M%C3%A4kel%C3%A4&amp;author=S.%20M.%20Zhang&amp;author=S.%20G.%20Rudd&amp;volume=14&amp;issue=1&amp;publication_year=2021&amp;pages=27&amp;pmid=33468238&amp;doi=10.1186/s13104-021-05445-7&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70044-bib-0011">
<span class="label">11.</span><cite>
Zheng S., Wang W., Aldahdooh J., et al., “SynergyFinder Plus: Toward Better Interpretation and Annotation of Drug Combination Screening Datasets,” Genomics, Proteomics &amp; Bioinformatics
20, no. 3 (2022): 587–596, 10.1016/j.gpb.2022.01.004.</cite> [<a href="https://doi.org/10.1016/j.gpb.2022.01.004" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9801064/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35085776/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Genomics,%20Proteomics%20&amp;%20Bioinformatics&amp;title=SynergyFinder%20Plus:%20Toward%20Better%20Interpretation%20and%20Annotation%20of%20Drug%20Combination%20Screening%20Datasets&amp;author=S.%20Zheng&amp;author=W.%20Wang&amp;author=J.%20Aldahdooh&amp;volume=20&amp;issue=3&amp;publication_year=2022&amp;pages=587-596&amp;pmid=35085776&amp;doi=10.1016/j.gpb.2022.01.004&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70044-bib-0012">
<span class="label">12.</span><cite>
Yadav B., Wennerberg K., Aittokallio T., and Tang J., “Searching for Drug Synergy in Complex Dose‐Response Landscapes Using an Interaction Potency Model,” Computational and Structural Biotechnology Journal
13 (2015): 504–513, 10.1016/j.csbj.2015.09.001.
</cite> [<a href="https://doi.org/10.1016/j.csbj.2015.09.001" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4759128/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26949479/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Computational%20and%20Structural%20Biotechnology%20Journal&amp;title=Searching%20for%20Drug%20Synergy%20in%20Complex%20Dose%E2%80%90Response%20Landscapes%20Using%20an%20Interaction%20Potency%20Model&amp;author=B.%20Yadav&amp;author=K.%20Wennerberg&amp;author=T.%20Aittokallio&amp;author=J.%20Tang&amp;volume=13&amp;publication_year=2015&amp;pages=504-513&amp;pmid=26949479&amp;doi=10.1016/j.csbj.2015.09.001&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70044-bib-0013">
<span class="label">13.</span><cite>
Tang Z., Li C., Kang B., Gao G., Li C., and Zhang Z., “GEPIA: A Web Server for Cancer and Normal Gene Expression Profiling and Interactive Analyses,” Nucleic Acids Research
45, no. W1 (2017): W98–W102, 10.1093/nar/gkx247.
</cite> [<a href="https://doi.org/10.1093/nar/gkx247" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5570223/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28407145/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nucleic%20Acids%20Research&amp;title=GEPIA:%20A%20Web%20Server%20for%20Cancer%20and%20Normal%20Gene%20Expression%20Profiling%20and%20Interactive%20Analyses&amp;author=Z.%20Tang&amp;author=C.%20Li&amp;author=B.%20Kang&amp;author=G.%20Gao&amp;author=C.%20Li&amp;volume=45&amp;issue=W1&amp;publication_year=2017&amp;pages=W98-W102&amp;pmid=28407145&amp;doi=10.1093/nar/gkx247&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70044-bib-0014">
<span class="label">14.</span><cite>
Győrffy B., “Transcriptome‐Level Discovery of Survival‐Associated Biomarkers and Therapy Targets in Non‐Small‐Cell Lung Cancer,” British Journal of Pharmacology
181, no. 3 (2024): 362–374, 10.1111/bph.16257.
</cite> [<a href="https://doi.org/10.1111/bph.16257" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37783508/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=British%20Journal%20of%20Pharmacology&amp;title=Transcriptome%E2%80%90Level%20Discovery%20of%20Survival%E2%80%90Associated%20Biomarkers%20and%20Therapy%20Targets%20in%20Non%E2%80%90Small%E2%80%90Cell%20Lung%20Cancer&amp;author=B.%20Gy%C5%91rffy&amp;volume=181&amp;issue=3&amp;publication_year=2024&amp;pages=362-374&amp;pmid=37783508&amp;doi=10.1111/bph.16257&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70044-bib-0015">
<span class="label">15.</span><cite>
Győrffy B., “Discovery and Ranking of the Most Robust Prognostic Biomarkers in Serous Ovarian Cancer,” GeroScience
45, no. 3 (2023): 1889–1898, 10.1007/s11357-023-00742-4.
</cite> [<a href="https://doi.org/10.1007/s11357-023-00742-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10400493/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36856946/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=GeroScience&amp;title=Discovery%20and%20Ranking%20of%20the%20Most%20Robust%20Prognostic%20Biomarkers%20in%20Serous%20Ovarian%20Cancer&amp;author=B.%20Gy%C5%91rffy&amp;volume=45&amp;issue=3&amp;publication_year=2023&amp;pages=1889-1898&amp;pmid=36856946&amp;doi=10.1007/s11357-023-00742-4&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70044-bib-0016">
<span class="label">16.</span><cite>
Dixon S. J., Lemberg K. M., Lamprecht M. R., et al., “Ferroptosis: An Iron‐Dependent Form of Nonapoptotic Cell Death,” Cell
149, no. 5 (2012): 1060–1072, 10.1016/j.cell.2012.03.042.
</cite> [<a href="https://doi.org/10.1016/j.cell.2012.03.042" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3367386/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22632970/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cell&amp;title=Ferroptosis:%20An%20Iron%E2%80%90Dependent%20Form%20of%20Nonapoptotic%20Cell%20Death&amp;author=S.%20J.%20Dixon&amp;author=K.%20M.%20Lemberg&amp;author=M.%20R.%20Lamprecht&amp;volume=149&amp;issue=5&amp;publication_year=2012&amp;pages=1060-1072&amp;pmid=22632970&amp;doi=10.1016/j.cell.2012.03.042&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70044-bib-0017">
<span class="label">17.</span><cite>
Yang W. S., SriRamaratnam R., Welsch M. E., et al., “Regulation of Ferroptotic Cancer Cell Death by GPX4,” Cell
156, no. 1–2 (2014): 317–331, 10.1016/j.cell.2013.12.010.
</cite> [<a href="https://doi.org/10.1016/j.cell.2013.12.010" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4076414/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24439385/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cell&amp;title=Regulation%20of%20Ferroptotic%20Cancer%20Cell%20Death%20by%20GPX4&amp;author=W.%20S.%20Yang&amp;author=R.%20SriRamaratnam&amp;author=M.%20E.%20Welsch&amp;volume=156&amp;issue=1%E2%80%932&amp;publication_year=2014&amp;pages=317-331&amp;pmid=24439385&amp;doi=10.1016/j.cell.2013.12.010&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70044-bib-0018">
<span class="label">18.</span><cite>
DeAngelo SL, Zhao L, Dziechciarz S, et al., “Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer,” Cancer Research
85, no. 15 (2025): 2788–2804,  10.1158/0008-5472.CAN-24-3478.
</cite> [<a href="https://doi.org/10.1158/0008-5472.CAN-24-3478" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/40392234/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Research&amp;title=Recharacterization%20of%20the%20Tumor%20Suppressive%20Mechanism%20of%20RSL3%20Identifies%20the%20Selenoproteome%20as%20a%20Druggable%20Pathway%20in%20Colorectal%20Cancer&amp;author=SL%20DeAngelo&amp;author=L%20Zhao&amp;author=S%20Dziechciarz&amp;volume=85&amp;issue=15&amp;publication_year=2025&amp;pages=2788-2804&amp;pmid=40392234&amp;doi=10.1158/0008-5472.CAN-24-3478&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70044-bib-0019">
<span class="label">19.</span><cite>
Viswanathan V. S., Ryan M. J., Dhruv H. D., et al., “Dependency of a Therapy‐Resistant State of Cancer Cells on a Lipid Peroxidase Pathway,” Nature
547, no. 7664 (2017): 453–457, 10.1038/nature23007.
</cite> [<a href="https://doi.org/10.1038/nature23007" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5667900/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28678785/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Dependency%20of%20a%20Therapy%E2%80%90Resistant%20State%20of%20Cancer%20Cells%20on%20a%20Lipid%20Peroxidase%20Pathway&amp;author=V.%20S.%20Viswanathan&amp;author=M.%20J.%20Ryan&amp;author=H.%20D.%20Dhruv&amp;volume=547&amp;issue=7664&amp;publication_year=2017&amp;pages=453-457&amp;pmid=28678785&amp;doi=10.1038/nature23007&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70044-bib-0020">
<span class="label">20.</span><cite>
Gross M. I., Demo S. D., Dennison J. B., et al., “Antitumor Activity of the Glutaminase Inhibitor CB‐839 in Triple‐Negative Breast Cancer,” Molecular Cancer Therapeutics
13, no. 4 (2014): 890–901, 10.1158/1535-7163.MCT-13-0870.
</cite> [<a href="https://doi.org/10.1158/1535-7163.MCT-13-0870" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24523301/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Molecular%20Cancer%20Therapeutics&amp;title=Antitumor%20Activity%20of%20the%20Glutaminase%20Inhibitor%20CB%E2%80%90839%20in%20Triple%E2%80%90Negative%20Breast%20Cancer&amp;author=M.%20I.%20Gross&amp;author=S.%20D.%20Demo&amp;author=J.%20B.%20Dennison&amp;volume=13&amp;issue=4&amp;publication_year=2014&amp;pages=890-901&amp;pmid=24523301&amp;doi=10.1158/1535-7163.MCT-13-0870&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70044-bib-0021">
<span class="label">21.</span><cite>
Yang W. H., Qiu Y., Stamatatos O., Janowitz T., and Lukey M. J., “Enhancing the Efficacy of Glutamine Metabolism Inhibitors in Cancer Therapy,” Trends in Cancer
7, no. 8 (2021): 790–804, 10.1016/j.trecan.2021.04.003.
</cite> [<a href="https://doi.org/10.1016/j.trecan.2021.04.003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9064286/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34020912/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Trends%20in%20Cancer&amp;title=Enhancing%20the%20Efficacy%20of%20Glutamine%20Metabolism%20Inhibitors%20in%20Cancer%20Therapy&amp;author=W.%20H.%20Yang&amp;author=Y.%20Qiu&amp;author=O.%20Stamatatos&amp;author=T.%20Janowitz&amp;author=M.%20J.%20Lukey&amp;volume=7&amp;issue=8&amp;publication_year=2021&amp;pages=790-804&amp;pmid=34020912&amp;doi=10.1016/j.trecan.2021.04.003&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70044-bib-0022">
<span class="label">22.</span><cite>
Avramis V. I., “Asparaginases: Biochemical Pharmacology and Modes of Drug Resistance,” Anticancer Research
32, no. 7 (2012): 2423–2437.
</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/22753699/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Anticancer%20Research&amp;title=Asparaginases:%20Biochemical%20Pharmacology%20and%20Modes%20of%20Drug%20Resistance&amp;author=V.%20I.%20Avramis&amp;volume=32&amp;issue=7&amp;publication_year=2012&amp;pages=2423-2437&amp;pmid=22753699&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70044-bib-0023">
<span class="label">23.</span><cite>
Avramis V. I. and Panosyan E. H., “Pharmacokinetic/Pharmacodynamic Relationships of Asparaginase Formulations: The Past, the Present and Recommendations for the Future,” Clinical Pharmacokinetics
44, no. 4 (2005): 367–393, 10.2165/00003088-200544040-00003.
</cite> [<a href="https://doi.org/10.2165/00003088-200544040-00003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15828851/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clinical%20Pharmacokinetics&amp;title=Pharmacokinetic/Pharmacodynamic%20Relationships%20of%20Asparaginase%20Formulations:%20The%20Past,%20the%20Present%20and%20Recommendations%20for%20the%20Future&amp;author=V.%20I.%20Avramis&amp;author=E.%20H.%20Panosyan&amp;volume=44&amp;issue=4&amp;publication_year=2005&amp;pages=367-393&amp;pmid=15828851&amp;doi=10.2165/00003088-200544040-00003&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70044-bib-0024">
<span class="label">24.</span><cite>
Hudson C. D., Savadelis A., Nagaraj A. B., et al., “Altered Glutamine Metabolism in Platinum Resistant Ovarian Cancer,” Oncotarget
7, no. 27 (2016): 41637–41649, 10.18632/oncotarget.9317.
</cite> [<a href="https://doi.org/10.18632/oncotarget.9317" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5173084/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27191653/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncotarget&amp;title=Altered%20Glutamine%20Metabolism%20in%20Platinum%20Resistant%20Ovarian%20Cancer&amp;author=C.%20D.%20Hudson&amp;author=A.%20Savadelis&amp;author=A.%20B.%20Nagaraj&amp;volume=7&amp;issue=27&amp;publication_year=2016&amp;pages=41637-41649&amp;pmid=27191653&amp;doi=10.18632/oncotarget.9317&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70044-bib-0025">
<span class="label">25.</span><cite>
Guo J., Satoh K., Tabata S., Mori M., Tomita M., and Soga T., “Reprogramming of Glutamine Metabolism via Glutamine Synthetase Silencing Induces Cisplatin Resistance in A2780 Ovarian Cancer Cells,” BMC Cancer
21, no. 1 (2021): 174, 10.1186/s12885-021-07879-5.
</cite> [<a href="https://doi.org/10.1186/s12885-021-07879-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7891143/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33596851/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMC%20Cancer&amp;title=Reprogramming%20of%20Glutamine%20Metabolism%20via%20Glutamine%20Synthetase%20Silencing%20Induces%20Cisplatin%20Resistance%20in%20A2780%20Ovarian%20Cancer%20Cells&amp;author=J.%20Guo&amp;author=K.%20Satoh&amp;author=S.%20Tabata&amp;author=M.%20Mori&amp;author=M.%20Tomita&amp;volume=21&amp;issue=1&amp;publication_year=2021&amp;pages=174&amp;pmid=33596851&amp;doi=10.1186/s12885-021-07879-5&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70044-bib-0026">
<span class="label">26.</span><cite>
Obrist F., Michels J., Durand S., et al., “Metabolic Vulnerability of Cisplatin‐Resistant Cancers,” EMBO Journal
37, no. 14 (2018): e98597, 10.15252/embj.201798597.
</cite> [<a href="https://doi.org/10.15252/embj.201798597" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6043854/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29875130/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=EMBO%20Journal&amp;title=Metabolic%20Vulnerability%20of%20Cisplatin%E2%80%90Resistant%20Cancers&amp;author=F.%20Obrist&amp;author=J.%20Michels&amp;author=S.%20Durand&amp;volume=37&amp;issue=14&amp;publication_year=2018&amp;pages=e98597&amp;pmid=29875130&amp;doi=10.15252/embj.201798597&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70044-bib-0027">
<span class="label">27.</span><cite>
Wangpaichitr M., Wu C., Li Y. Y., et al., “Exploiting ROS and Metabolic Differences to Kill Cisplatin Resistant Lung Cancer,” Oncotarget
8, no. 30 (2017): 49275–49292, 10.18632/oncotarget.17568.
</cite> [<a href="https://doi.org/10.18632/oncotarget.17568" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5564767/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28525376/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncotarget&amp;title=Exploiting%20ROS%20and%20Metabolic%20Differences%20to%20Kill%20Cisplatin%20Resistant%20Lung%20Cancer&amp;author=M.%20Wangpaichitr&amp;author=C.%20Wu&amp;author=Y.%20Y.%20Li&amp;volume=8&amp;issue=30&amp;publication_year=2017&amp;pages=49275-49292&amp;pmid=28525376&amp;doi=10.18632/oncotarget.17568&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70044-bib-0028">
<span class="label">28.</span><cite>
Duan G., Shi M., Xie L., et al., “Increased Glutamine Consumption in Cisplatin‐Resistant Cells Has a Negative Impact on Cell Growth,” Scientific Reports
8, no. 1 (2018): 4067, 10.1038/s41598-018-21831-x.
</cite> [<a href="https://doi.org/10.1038/s41598-018-21831-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5840399/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29511244/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Scientific%20Reports&amp;title=Increased%20Glutamine%20Consumption%20in%20Cisplatin%E2%80%90Resistant%20Cells%20Has%20a%20Negative%20Impact%20on%20Cell%20Growth&amp;author=G.%20Duan&amp;author=M.%20Shi&amp;author=L.%20Xie&amp;volume=8&amp;issue=1&amp;publication_year=2018&amp;pages=4067&amp;pmid=29511244&amp;doi=10.1038/s41598-018-21831-x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70044-bib-0029">
<span class="label">29.</span><cite>
Sullivan E. J., Kurtoglu M., Brenneman R., Liu H., and Lampidis T. J., “Targeting Cisplatin‐Resistant Human Tumor Cells With Metabolic Inhibitors,” Cancer Chemotherapy and Pharmacology
73, no. 2 (2014): 417–427, 10.1007/s00280-013-2366-8.
</cite> [<a href="https://doi.org/10.1007/s00280-013-2366-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24352250/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Chemotherapy%20and%20Pharmacology&amp;title=Targeting%20Cisplatin%E2%80%90Resistant%20Human%20Tumor%20Cells%20With%20Metabolic%20Inhibitors&amp;author=E.%20J.%20Sullivan&amp;author=M.%20Kurtoglu&amp;author=R.%20Brenneman&amp;author=H.%20Liu&amp;author=T.%20J.%20Lampidis&amp;volume=73&amp;issue=2&amp;publication_year=2014&amp;pages=417-427&amp;pmid=24352250&amp;doi=10.1007/s00280-013-2366-8&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70044-bib-0030">
<span class="label">30.</span><cite>
Wu Y. Y., Law Y. Y., Huang Y. W., et al., “Glutamine Metabolism Controls Amphiregulin‐Facilitated Chemoresistance to Cisplatin in Human Chondrosarcoma,” International Journal of Biological Sciences
19, no. 16 (2023): 5174–5186, 10.7150/ijbs.86116.
</cite> [<a href="https://doi.org/10.7150/ijbs.86116" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10620823/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37928274/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=International%20Journal%20of%20Biological%20Sciences&amp;title=Glutamine%20Metabolism%20Controls%20Amphiregulin%E2%80%90Facilitated%20Chemoresistance%20to%20Cisplatin%20in%20Human%20Chondrosarcoma&amp;author=Y.%20Y.%20Wu&amp;author=Y.%20Y.%20Law&amp;author=Y.%20W.%20Huang&amp;volume=19&amp;issue=16&amp;publication_year=2023&amp;pages=5174-5186&amp;pmid=37928274&amp;doi=10.7150/ijbs.86116&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70044-bib-0031">
<span class="label">31.</span><cite>
Okuno S., Sato H., Kuriyama‐Matsumura K., et al., “Role of Cystine Transport in Intracellular Glutathione Level and Cisplatin Resistance in Human Ovarian Cancer Cell Lines,” British Journal of Cancer
88, no. 6 (2003): 951–956, 10.1038/sj.bjc.6600786.
</cite> [<a href="https://doi.org/10.1038/sj.bjc.6600786" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2377069/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12644836/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=British%20Journal%20of%20Cancer&amp;title=Role%20of%20Cystine%20Transport%20in%20Intracellular%20Glutathione%20Level%20and%20Cisplatin%20Resistance%20in%20Human%20Ovarian%20Cancer%20Cell%20Lines&amp;author=S.%20Okuno&amp;author=H.%20Sato&amp;author=K.%20Kuriyama%E2%80%90Matsumura&amp;volume=88&amp;issue=6&amp;publication_year=2003&amp;pages=951-956&amp;pmid=12644836&amp;doi=10.1038/sj.bjc.6600786&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70044-bib-0032">
<span class="label">32.</span><cite>
Drayton R. M., Dudziec E., Peter S., et al., “Reduced Expression of miRNA‐27a Modulates Cisplatin Resistance in Bladder Cancer by Targeting the Cystine/Glutamate Exchanger SLC7A11,” Clinical Cancer Research
20, no. 7 (2014): 1990–2000, 10.1158/1078-0432.CCR-13-2805.
</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-13-2805" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3974662/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24516043/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clinical%20Cancer%20Research&amp;title=Reduced%20Expression%20of%20miRNA%E2%80%9027a%20Modulates%20Cisplatin%20Resistance%20in%20Bladder%20Cancer%20by%20Targeting%20the%20Cystine/Glutamate%20Exchanger%20SLC7A11&amp;author=R.%20M.%20Drayton&amp;author=E.%20Dudziec&amp;author=S.%20Peter&amp;volume=20&amp;issue=7&amp;publication_year=2014&amp;pages=1990-2000&amp;pmid=24516043&amp;doi=10.1158/1078-0432.CCR-13-2805&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70044-bib-0033">
<span class="label">33.</span><cite>
Luo Y., Xiang W., Liu Z., et al., “Functional Role of the SLC7A11‐AS1/xCT Axis in the Development of Gastric Cancer Cisplatin‐Resistance by a GSH‐Dependent Mechanism,” Free Radical Biology &amp; Medicine
184 (2022): 53–65, 10.1016/j.freeradbiomed.2022.03.026.
</cite> [<a href="https://doi.org/10.1016/j.freeradbiomed.2022.03.026" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35367340/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Free%20Radical%20Biology%20&amp;%20Medicine&amp;title=Functional%20Role%20of%20the%20SLC7A11%E2%80%90AS1/xCT%20Axis%20in%20the%20Development%20of%20Gastric%20Cancer%20Cisplatin%E2%80%90Resistance%20by%20a%20GSH%E2%80%90Dependent%20Mechanism&amp;author=Y.%20Luo&amp;author=W.%20Xiang&amp;author=Z.%20Liu&amp;volume=184&amp;publication_year=2022&amp;pages=53-65&amp;pmid=35367340&amp;doi=10.1016/j.freeradbiomed.2022.03.026&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70044-bib-0034">
<span class="label">34.</span><cite>
Li Y., Yan H., Xu X., Liu H., Wu C., and Zhao L., “Erastin/Sorafenib Induces Cisplatin‐Resistant Non‐Small Cell Lung Cancer Cell Ferroptosis Through Inhibition of the Nrf2/xCT Pathway,” Oncology Letters
19, no. 1 (2020): 323–333, 10.3892/ol.2019.11066.
</cite> [<a href="https://doi.org/10.3892/ol.2019.11066" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6923844/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31897145/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncology%20Letters&amp;title=Erastin/Sorafenib%20Induces%20Cisplatin%E2%80%90Resistant%20Non%E2%80%90Small%20Cell%20Lung%20Cancer%20Cell%20Ferroptosis%20Through%20Inhibition%20of%20the%20Nrf2/xCT%20Pathway&amp;author=Y.%20Li&amp;author=H.%20Yan&amp;author=X.%20Xu&amp;author=H.%20Liu&amp;author=C.%20Wu&amp;volume=19&amp;issue=1&amp;publication_year=2020&amp;pages=323-333&amp;pmid=31897145&amp;doi=10.3892/ol.2019.11066&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70044-bib-0035">
<span class="label">35.</span><cite>
Timmerman L. A., Holton T., Yuneva M., et al., “Glutamine Sensitivity Analysis Identifies the xCT Antiporter as a Common Triple‐Negative Breast Tumor Therapeutic Target,” Cancer Cell
24, no. 4 (2013): 450–465, 10.1016/j.ccr.2013.08.020.
</cite> [<a href="https://doi.org/10.1016/j.ccr.2013.08.020" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3931310/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24094812/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Cell&amp;title=Glutamine%20Sensitivity%20Analysis%20Identifies%20the%20xCT%20Antiporter%20as%20a%20Common%20Triple%E2%80%90Negative%20Breast%20Tumor%20Therapeutic%20Target&amp;author=L.%20A.%20Timmerman&amp;author=T.%20Holton&amp;author=M.%20Yuneva&amp;volume=24&amp;issue=4&amp;publication_year=2013&amp;pages=450-465&amp;pmid=24094812&amp;doi=10.1016/j.ccr.2013.08.020&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70044-bib-0036">
<span class="label">36.</span><cite>
Muir A., Danai L. V., Gui D. Y., Waingarten C. Y., Lewis C. A., and Vander Heiden M. G., “Environmental Cystine Drives Glutamine Anaplerosis and Sensitizes Cancer Cells to Glutaminase Inhibition,” eLife
6 (2017): e27713, 10.7554/eLife.27713.
</cite> [<a href="https://doi.org/10.7554/eLife.27713" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5589418/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28826492/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=eLife&amp;title=Environmental%20Cystine%20Drives%20Glutamine%20Anaplerosis%20and%20Sensitizes%20Cancer%20Cells%20to%20Glutaminase%20Inhibition&amp;author=A.%20Muir&amp;author=L.%20V.%20Danai&amp;author=D.%20Y.%20Gui&amp;author=C.%20Y.%20Waingarten&amp;author=C.%20A.%20Lewis&amp;volume=6&amp;publication_year=2017&amp;pages=e27713&amp;pmid=28826492&amp;doi=10.7554/eLife.27713&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70044-bib-0037">
<span class="label">37.</span><cite>
Sayin V. I., LeBoeuf S. E., Singh S. X., et al., “Activation of the NRF2 Antioxidant Program Generates an Imbalance in Central Carbon Metabolism in Cancer,” eLife
6 (2017): e28083, 10.7554/eLife.28083.
</cite> [<a href="https://doi.org/10.7554/eLife.28083" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5624783/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28967864/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=eLife&amp;title=Activation%20of%20the%20NRF2%20Antioxidant%20Program%20Generates%20an%20Imbalance%20in%20Central%20Carbon%20Metabolism%20in%20Cancer&amp;author=V.%20I.%20Sayin&amp;author=S.%20E.%20LeBoeuf&amp;author=S.%20X.%20Singh&amp;volume=6&amp;publication_year=2017&amp;pages=e28083&amp;pmid=28967864&amp;doi=10.7554/eLife.28083&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70044-bib-0038">
<span class="label">38.</span><cite>
Ji X., Qian J., Rahman S. M. J., et al., “xCT (SLC7A11)‐Mediated Metabolic Reprogramming Promotes Non‐Small Cell Lung Cancer Progression,” Oncogene
37, no. 36 (2018): 5007–5019, 10.1038/s41388-018-0307-z.
</cite> [<a href="https://doi.org/10.1038/s41388-018-0307-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6127081/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29789716/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncogene&amp;title=xCT%20(SLC7A11)%E2%80%90Mediated%20Metabolic%20Reprogramming%20Promotes%20Non%E2%80%90Small%20Cell%20Lung%20Cancer%20Progression&amp;author=X.%20Ji&amp;author=J.%20Qian&amp;author=S.%20M.%20J.%20Rahman&amp;volume=37&amp;issue=36&amp;publication_year=2018&amp;pages=5007-5019&amp;pmid=29789716&amp;doi=10.1038/s41388-018-0307-z&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70044-bib-0039">
<span class="label">39.</span><cite>
Wang L., Liu Y., Du T., et al., “ATF3 promotes erastin‐induced ferroptosis by suppressing system Xc,” Cell Death and Differentiation
27, no. 2 (2020): 662–675, 10.1038/s41418-019-0380-z.
</cite> [<a href="https://doi.org/10.1038/s41418-019-0380-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7206049/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31273299/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cell%20Death%20and%20Differentiation&amp;title=ATF3%20promotes%20erastin%E2%80%90induced%20ferroptosis%20by%20suppressing%20system%20Xc&amp;author=L.%20Wang&amp;author=Y.%20Liu&amp;author=T.%20Du&amp;volume=27&amp;issue=2&amp;publication_year=2020&amp;pages=662-675&amp;pmid=31273299&amp;doi=10.1038/s41418-019-0380-z&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70044-bib-0040">
<span class="label">40.</span><cite>
Zhang Y., Swanda R. V., Nie L., et al., “mTORC1 Couples Cyst(e)ine Availability With GPX4 Protein Synthesis and Ferroptosis Regulation,” Nature Communications
12, no. 1 (2021): 1589, 10.1038/s41467-021-21841-w.</cite> [<a href="https://doi.org/10.1038/s41467-021-21841-w" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7952727/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33707434/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Communications&amp;title=mTORC1%20Couples%20Cyst(e)ine%20Availability%20With%20GPX4%20Protein%20Synthesis%20and%20Ferroptosis%20Regulation&amp;author=Y.%20Zhang&amp;author=R.%20V.%20Swanda&amp;author=L.%20Nie&amp;volume=12&amp;issue=1&amp;publication_year=2021&amp;pages=1589&amp;pmid=33707434&amp;doi=10.1038/s41467-021-21841-w&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70044-bib-0041">
<span class="label">41.</span><cite>
Yuan Q., Yin L., He J., et al., “Metabolism of Asparagine in the Physiological State and Cancer,” Cell Communication and Signaling: CCS
22, no. 1 (2024): 163, 10.1186/s12964-024-01540-x.
</cite> [<a href="https://doi.org/10.1186/s12964-024-01540-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10916255/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38448969/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cell%20Communication%20and%20Signaling:%20CCS&amp;title=Metabolism%20of%20Asparagine%20in%20the%20Physiological%20State%20and%20Cancer&amp;author=Q.%20Yuan&amp;author=L.%20Yin&amp;author=J.%20He&amp;volume=22&amp;issue=1&amp;publication_year=2024&amp;pages=163&amp;pmid=38448969&amp;doi=10.1186/s12964-024-01540-x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70044-bib-0042">
<span class="label">42.</span><cite>
Liao J., Liu P. P., Hou G., et al., “Regulation of Stem‐Like Cancer Cells by Glutamine Through β‐Catenin Pathway Mediated by Redox Signaling,” Molecular Cancer
16, no. 1 (2017): 51, 10.1186/s12943-017-0623-x.
</cite> [<a href="https://doi.org/10.1186/s12943-017-0623-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5331650/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28245869/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Molecular%20Cancer&amp;title=Regulation%20of%20Stem%E2%80%90Like%20Cancer%20Cells%20by%20Glutamine%20Through%20%CE%B2%E2%80%90Catenin%20Pathway%20Mediated%20by%20Redox%20Signaling&amp;author=J.%20Liao&amp;author=P.%20P.%20Liu&amp;author=G.%20Hou&amp;volume=16&amp;issue=1&amp;publication_year=2017&amp;pages=51&amp;pmid=28245869&amp;doi=10.1186/s12943-017-0623-x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70044-bib-0043">
<span class="label">43.</span><cite>
Sugimoto K., Suzuki H. I., Fujimura T., et al., “A Clinically Attainable Dose of L‐Asparaginase Targets Glutamine Addiction in Lymphoid Cell Lines,” Cancer Science
106, no. 11 (2015): 1534–1543, 10.1111/cas.12807.
</cite> [<a href="https://doi.org/10.1111/cas.12807" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4714686/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26331698/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Science&amp;title=A%20Clinically%20Attainable%20Dose%20of%20L%E2%80%90Asparaginase%20Targets%20Glutamine%20Addiction%20in%20Lymphoid%20Cell%20Lines&amp;author=K.%20Sugimoto&amp;author=H.%20I.%20Suzuki&amp;author=T.%20Fujimura&amp;volume=106&amp;issue=11&amp;publication_year=2015&amp;pages=1534-1543&amp;pmid=26331698&amp;doi=10.1111/cas.12807&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70044-bib-0044">
<span class="label">44.</span><cite>
Trinh A., Khamari R., Fovez Q., et al., “Antimetabolic Cooperativity With the Clinically Approved L‐Asparaginase and Tyrosine Kinase Inhibitors to Eradicate CML Stem Cells,” Molecular Metabolism
55 (2022): 101410, 10.1016/j.molmet.2021.101410.
</cite> [<a href="https://doi.org/10.1016/j.molmet.2021.101410" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8732793/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34863941/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Molecular%20Metabolism&amp;title=Antimetabolic%20Cooperativity%20With%20the%20Clinically%20Approved%20L%E2%80%90Asparaginase%20and%20Tyrosine%20Kinase%20Inhibitors%20to%20Eradicate%20CML%20Stem%20Cells&amp;author=A.%20Trinh&amp;author=R.%20Khamari&amp;author=Q.%20Fovez&amp;volume=55&amp;publication_year=2022&amp;pages=101410&amp;pmid=34863941&amp;doi=10.1016/j.molmet.2021.101410&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70044-bib-0045">
<span class="label">45.</span><cite>
Willems L., Jacque N., Jacquel A., et al., “Inhibiting Glutamine Uptake Represents an Attractive New Strategy for Treating Acute Myeloid Leukemia,” Blood
122, no. 20 (2013): 3521–3532, 10.1182/blood-2013-03-493163.
</cite> [<a href="https://doi.org/10.1182/blood-2013-03-493163" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3829119/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24014241/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=Inhibiting%20Glutamine%20Uptake%20Represents%20an%20Attractive%20New%20Strategy%20for%20Treating%20Acute%20Myeloid%20Leukemia&amp;author=L.%20Willems&amp;author=N.%20Jacque&amp;author=A.%20Jacquel&amp;volume=122&amp;issue=20&amp;publication_year=2013&amp;pages=3521-3532&amp;pmid=24014241&amp;doi=10.1182/blood-2013-03-493163&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70044-bib-0046">
<span class="label">46.</span><cite>
Chan W. K., Horvath T. D., Tan L., et al., “Glutaminase Activity of L‐Asparaginase Contributes to Durable Preclinical Activity against Acute Lymphoblastic Leukemia,” Molecular Cancer Therapeutics
18, no. 9 (2019): 1587–1592, 10.1158/1535-7163.MCT-18-1329.
</cite> [<a href="https://doi.org/10.1158/1535-7163.MCT-18-1329" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6726508/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31209181/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Molecular%20Cancer%20Therapeutics&amp;title=Glutaminase%20Activity%20of%20L%E2%80%90Asparaginase%20Contributes%20to%20Durable%20Preclinical%20Activity%20against%20Acute%20Lymphoblastic%20Leukemia&amp;author=W.%20K.%20Chan&amp;author=T.%20D.%20Horvath&amp;author=L.%20Tan&amp;volume=18&amp;issue=9&amp;publication_year=2019&amp;pages=1587-1592&amp;pmid=31209181&amp;doi=10.1158/1535-7163.MCT-18-1329&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70044-bib-0047">
<span class="label">47.</span><cite>
Haskell C. M., Canellos G. P., Leventhal B. G., et al., “L‐Asparaginase: Therapeutic and Toxic Effects in Patients With Neoplastic Disease,” New England Journal of Medicine
281, no. 19 (1969): 1028–1034, 10.1056/NEJM196911062811902.
</cite> [<a href="https://doi.org/10.1056/NEJM196911062811902" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/4898857/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=New%20England%20Journal%20of%20Medicine&amp;title=L%E2%80%90Asparaginase:%20Therapeutic%20and%20Toxic%20Effects%20in%20Patients%20With%20Neoplastic%20Disease&amp;author=C.%20M.%20Haskell&amp;author=G.%20P.%20Canellos&amp;author=B.%20G.%20Leventhal&amp;volume=281&amp;issue=19&amp;publication_year=1969&amp;pages=1028-1034&amp;pmid=4898857&amp;doi=10.1056/NEJM196911062811902&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70044-bib-0048">
<span class="label">48.</span><cite>
Hays J. L., Kim G., Walker A., et al., “A Phase II Clinical Trial of Polyethylene Glycol‐Conjugated L‐Asparaginase in Patients With Advanced Ovarian Cancer: Early Closure for Safety,” Molecular and Clinical Oncology
1, no. 3 (2013): 565–569, 10.3892/mco.2013.99.
</cite> [<a href="https://doi.org/10.3892/mco.2013.99" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3916154/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24649212/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Molecular%20and%20Clinical%20Oncology&amp;title=A%20Phase%20II%20Clinical%20Trial%20of%20Polyethylene%20Glycol%E2%80%90Conjugated%20L%E2%80%90Asparaginase%20in%20Patients%20With%20Advanced%20Ovarian%20Cancer:%20Early%20Closure%20for%20Safety&amp;author=J.%20L.%20Hays&amp;author=G.%20Kim&amp;author=A.%20Walker&amp;volume=1&amp;issue=3&amp;publication_year=2013&amp;pages=565-569&amp;pmid=24649212&amp;doi=10.3892/mco.2013.99&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70044-bib-0049">
<span class="label">49.</span><cite>
Van Trimpont M., Peeters E., De Visser Y., et al., “Novel Insights on the Use of L‐Asparaginase as an Efficient and Safe Anti‐Cancer Therapy,” Cancers (Basel)
14, no. 4 (2022): 902, 10.3390/cancers14040902.
</cite> [<a href="https://doi.org/10.3390/cancers14040902" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8870365/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35205650/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancers%20(Basel)&amp;title=Novel%20Insights%20on%20the%20Use%20of%20L%E2%80%90Asparaginase%20as%20an%20Efficient%20and%20Safe%20Anti%E2%80%90Cancer%20Therapy&amp;author=M.%20Van%20Trimpont&amp;author=E.%20Peeters&amp;author=Y.%20De%20Visser&amp;volume=14&amp;issue=4&amp;publication_year=2022&amp;pages=902&amp;pmid=35205650&amp;doi=10.3390/cancers14040902&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70044-bib-0050">
<span class="label">50.</span><cite>
Sun J., Nagel R., Zaal E. A., et al., “SLC1A3 contributes to L‐asparaginase resistance in solid tumors,” EMBO Journal
38, no. 21 (2019): e102147, 10.15252/embj.2019102147.
</cite> [<a href="https://doi.org/10.15252/embj.2019102147" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6826201/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31523835/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=EMBO%20Journal&amp;title=SLC1A3%20contributes%20to%20L%E2%80%90asparaginase%20resistance%20in%20solid%20tumors&amp;author=J.%20Sun&amp;author=R.%20Nagel&amp;author=E.%20A.%20Zaal&amp;volume=38&amp;issue=21&amp;publication_year=2019&amp;pages=e102147&amp;pmid=31523835&amp;doi=10.15252/embj.2019102147&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70044-bib-0051">
<span class="label">51.</span><cite>
Mueller C., Al‐Batran S., Jaeger E., et al., “A Phase IIa Study of PEGylated Glutaminase (PEG‐PGA) Plus 6‐Diazo‐5‐Oxo‐L‐Norleucine (DON) in Patients With Advanced Refractory Solid Tumors,” Journal of Clinical Oncology
26, no. 15_suppl (2008): 2533, 10.1200/jco.2008.26.15_suppl.2533.</cite> [<a href="https://doi.org/10.1200/jco.2008.26.15_suppl.2533" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Clinical%20Oncology&amp;title=A%20Phase%20IIa%20Study%20of%20PEGylated%20Glutaminase%20(PEG%E2%80%90PGA)%20Plus%206%E2%80%90Diazo%E2%80%905%E2%80%90Oxo%E2%80%90L%E2%80%90Norleucine%20(DON)%20in%20Patients%20With%20Advanced%20Refractory%20Solid%20Tumors&amp;author=C.%20Mueller&amp;author=S.%20Al%E2%80%90Batran&amp;author=E.%20Jaeger&amp;volume=26&amp;issue=15_suppl&amp;publication_year=2008&amp;pages=2533&amp;doi=10.1200/jco.2008.26.15_suppl.2533&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70044-bib-0052">
<span class="label">52.</span><cite>
Kumar M., Leekha A., Nandy S., et al., “Enzymatic Depletion of Circulating Glutamine Is Immunosuppressive in Cancers,” iScience
27, no. 6 (2024): 109817, 10.1016/j.isci.2024.109817.
</cite> [<a href="https://doi.org/10.1016/j.isci.2024.109817" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11103382/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38770139/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=iScience&amp;title=Enzymatic%20Depletion%20of%20Circulating%20Glutamine%20Is%20Immunosuppressive%20in%20Cancers&amp;author=M.%20Kumar&amp;author=A.%20Leekha&amp;author=S.%20Nandy&amp;volume=27&amp;issue=6&amp;publication_year=2024&amp;pages=109817&amp;pmid=38770139&amp;doi=10.1016/j.isci.2024.109817&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="fcp70044-bib-0053">
<span class="label">53.</span><cite>
Palmer A. C., Chidley C., and Sorger P. K., “A Curative Combination Cancer Therapy Achieves High Fractional Cell Killing Through Low Cross‐Resistance and Drug Additivity,” eLife
8 (2019): e50036, 10.7554/eLife.50036.
</cite> [<a href="https://doi.org/10.7554/eLife.50036" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6897534/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31742555/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=eLife&amp;title=A%20Curative%20Combination%20Cancer%20Therapy%20Achieves%20High%20Fractional%20Cell%20Killing%20Through%20Low%20Cross%E2%80%90Resistance%20and%20Drug%20Additivity&amp;author=A.%20C.%20Palmer&amp;author=C.%20Chidley&amp;author=P.%20K.%20Sorger&amp;volume=8&amp;publication_year=2019&amp;pages=e50036&amp;pmid=31742555&amp;doi=10.7554/eLife.50036&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adsm93_" lang="en" class="supplementary-materials"><h3 class="pmc_sec_title">Supplementary Materials</h3>
<section class="sm xbox font-sm" id="db_ds_supplementary-material1_reqid_"><div class="caption p"><p>
<strong>Figure S1:</strong> Kaplan–Meier survival analyses were performed using the KM‐plotter platform for lung and ovarian cancer—as detailed in Materials and Methods—stratifying patients by median <em>SLC7A11</em> expression. In lung cancer (<em>n</em> = 2166), high <em>SLC7A11</em> expression was associated with significantly worse overall survival (log‐rank <em>p</em> = 0.019; hazard ratio [HR] = 1.15). In contrast, in ovarian cancer (<em>n</em> = 1435), SLC7A11 expression was not significantly associated with survival (log‐rank <em>p</em> = 0.27; HR = 0.93).</p></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/12335911/bin/FCP-39-0-s001.pdf" data-ga-action="click_feat_suppl" class="usa-link">FCP-39-0-s001.pdf</a><sup> (658.8KB, pdf) </sup>
</div></div></section></section><section id="_adda93_" lang="en" class="data-availability-statement"><h3 class="pmc_sec_title">Data Availability Statement</h3>
<p>Data can be made available by the authors upon request.</p></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Fundamental &amp; Clinical Pharmacology are provided here courtesy of <strong>Wiley</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1111/fcp.70044"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/FCP-39-0.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (1.8 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12335911/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12335911/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12335911%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12335911/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12335911/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12335911/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40784667/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12335911/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40784667/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12335911/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12335911/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="IM2hAKOV4fi76YoYd7EP7L56V5gYNWOjBjPFS1aYuNP6SuDr0iBJ0ZIMkYMdZvUN">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Web Policies

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    FOIA

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    HHS Vulnerability Disclosure

    
</a>

                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Help

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Accessibility

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Careers

    
</a>

                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    NLM

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    NIH

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    HHS

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    USA.gov

    
</a>

                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-370d5dd6.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-917ba005.js"></script>
    
    

    </body>
</html>
